Document:

<PAGE>
                                                                 Exhibit 10.1

             AMENDED AND RESTATED MANUFACTURING AND SUPPLY AGREEMENT

This Amended and Restated Manufacturing and Supply Agreement (the "Agreement")
is entered into effective as of April 24, 2003 ("Effective Date"), by and
between APG, an Indiana corporation ("APG"), and Connetics Corporation, a
Delaware corporation ("Connetics"). APG and Connetics are each referred to as a
"Party" to this Agreement, and collectively as the "Parties."

                                   BACKGROUND

A.       Connetics desires to use APG's facilities, resources and expertise to
         manufacture the Products, as defined below, and APG desires to act as a
         contract manufacturer of the Products agreed to by both Parties in
         accordance with the terms and conditions set forth in this Agreement.

B.       Connetics and APG previously entered into a Quality and Technical
         Agreement, dated January 8, 2002, as amended effective September 13,
         2002.

C.       Connetics and APG previously entered into a Manufacturing and Supply
         Agreement dated January 1, 2002, which was amended on July 1, 2002 (the
         "Original Agreement"). The Parties desire to amend and restate the
         Original Agreement to encompass the matters set forth in this
         Agreement.

D.       Upon the execution of this Agreement by the Parties, Connetics desires
         to pre-pay [*] for future development work and Products
         (the "Payment").

E.       [*]

NOW, THEREFORE, in consideration of the above premises and the mutual covenants
set forth below, APG and Connetics agree as follows:

                                    AGREEMENT

                                    ARTICLE 1
                                   DEFINITIONS

For the purposes of this Agreement, in addition to terms defined elsewhere in
this Agreement, the following capitalized terms shall have the following
meanings:

"AFFILIATE" means any corporation or other business entity controlled by,
controlling or under common control with a party hereto. For this purpose
"control" shall mean direct or indirect

                                                                          PAGE 1

[*]  Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to
the omitted portions.
<PAGE>

beneficial ownership of fifty percent (50%) or more of the voting stock, or a
fifty percent (50%) or more interest in the income of, such corporation or other
business entity.

"ANNUAL CREDIT" shall have the meaning set forth in SECTION 4.5.

"API" means active pharmaceutical ingredient.

"BATCH" shall have the meaning set forth in the Quality Agreement.

"CERTIFICATE OF ANALYSIS" means a summary of the quality control testing, as
described in the Specifications, performed by APG for Finished Product supplied
under this Agreement.

"CHANGE" shall have the meaning set forth in the Quality Agreement.

"cGMPs" means the current Good Manufacturing Practices of the FDA.

"COMMERCIALLY REASONABLE EFFORTS" means the effort by APG or Connetics to
deploy, in light of prevailing circumstances and taking into account obligations
and commitments to third parties, sufficient resources, capital equipment,
material and labor as might reasonably be expected to achieve in a commercially
appropriate time-scale, the benefits which are reasonably anticipated to accrue
to APG and Connetics from the commercial exploitation of the Products, and if
the Commercially Reasonable Efforts are to be directed to a specific goal, then
the achievement of that goal.

"CONFIDENTIAL INFORMATION" shall have the meaning set forth in SECTION 7.1.

"CONNETICS REPRESENTATIVE" means the person designated by Connetics who shall be
primarily on site at APG's facility.

"DATE OF MANUFACTURE" shall have the meaning set forth in the Quality Agreement.

"DEVELOPMENT AGREEMENT" means any separate agreement entered into by the Parties
with respect to a potential Product that is not yet ready to be manufactured on
a commercial scale, including the requirements surrounding production of units
of Product and Placebo appropriately labeled for use in Connetics' clinical
trials (in amounts to be specified by Connetics, as required). Each such
Development Agreement shall, when executed, be appended to this Agreement as an
EXHIBIT E (sequentially numbered as Exhibits E-1, E-2, etc.).

"DMF" means the drug master file for a Product, as filed by APG with the FDA.

"FDA" means the Food and Drug Administration of the United States of America.

"FINISHED PRODUCT" shall have the meaning set forth in the Quality Agreement.

"IND" means an Investigational New Drug Application for a Product, as filed by
Connetics with the FDA.

                                                                          PAGE 2

<PAGE>

"INITIAL TERM" shall have the meaning set forth in SECTION 10.1.

"LABELING" means the primary container label, secondary packaging, package
insert, shelf pack and shipper label specific to finished Product, including
Placebo, manufactured pursuant to this Agreement.

"LOSSES" shall have the meaning set forth in SECTION 11.1.

"MANUFACTURING FEE" means the fee paid by Connetics to APG for services required
to manufacture and package Products. The Manufacturing Fee is quoted in single
final Product Unit increments (i.e., by the can, bottle, or tube), and will be
set for each Product and for each size or formulation. . The Manufacturing Fee
shall include services for incoming inspection of materials (including costs
associated with establishing, testing and storing Raw Materials or Components),
compounding of bulk, packaging Product, testing Product for release, making
Product ready for shipment, and minimum product documentation (one copy of
Certificate of Analysis, batch records).

"MANUFACTURING STANDARDS" means the specifications for manufacturing, packaging,
labeling and storing the Products set forth in the Specifications, the master
batch record, cGMPs, MSDSs, and all other applicable U.S. laws and regulations.

"MSDS" means material safety data sheet(s).

"NDA" means a New Drug Application for a Product, as filed by Connetics with,
and approved by the FDA.

"PAYMENT" shall have the meaning set forth in RECITAL D.

"PLACEBO" means a Product adjusted to be formulated without the active
ingredient.

"PRODUCT(s)" means the products described on EXHIBIT A to this Agreement, as it
may be properly amended from time to time by agreement of the Parties, and which
is incorporated by this reference as though fully set forth in this paragraph.

"QUALITY AGREEMENT" means the Agreement set forth as EXHIBIT C to this Agreement
and incorporated by this reference as though fully set forth in this Agreement,
as it may be amended from time to time.

"RAW MATERIALS" means any and all raw materials and components other than the
API needed by APG to manufacture and supply Product according to the terms and
conditions of this Agreement.

"REGULATORY AUTHORITY" means the FDA or any equivalent or additional
governmental or regulatory agencies having jurisdiction with respect to APG,
APG's facilities, or the Products.

"SPECIFICATIONS" means the specifications established by Connetics in writing
for the manufacture of any Product.

                                                                          PAGE 3

<PAGE>

"UNIQUE MATERIALS" shall have the meaning set forth in SECTION 3.12 of this
Agreement.

"UNIT" means the Product in the package sizes set forth in the Specifications.
The trade or sample package may be changed from time to time and the term "Unit"
shall refer to the Product in such changed package.

                                    ARTICLE 2
                         SPECIFICATIONS AND MANUFACTURE

2.1      Manufacture of Products. During the term of this Agreement, and subject
         to the terms and conditions of this Agreement, APG shall formulate,
         fill and package the Products (including Placebo) in accordance with
         their respective Specifications, according to the terms of this
         Agreement and the Quality Agreement, as they may be amended from time
         to time. The Parties may mutually agree to alter the Specifications or
         to amend the Quality Agreement from time to time by written agreement
         without the necessity of amending this Agreement.

2.2      Conformance to Specifications. Products (and jointly approved for the
         purposes of this section, the Placebo) shall conform to the
         Specifications, the terms of the Quality Agreement, and all
         specifications provided in Connetics' IND or NDA. Notwithstanding the
         foregoing, if Connetics accepts Product in accordance with the
         provisions of this Agreement and the Quality Agreement, this SECTION
         2.2 shall be deemed to have been satisfied.

2.3      Labeling. APG will label and package Product in finished form, pursuant
         to a firm purchase order accepted by APG as described in SECTION 3.4.
         Connetics shall be responsible for the origination of artwork and text,
         and shall make all final decisions with regard to the Labeling.
         Connetics shall be responsible for assuring that such Labeling conforms
         to all applicable laws.

2.4      Raw Materials. APG shall have the sole responsibility to source all API
         and Raw Materials, including all quality control responsibility for
         such Raw Materials. APG shall secure reliable sources and maintain
         sufficient quantities of the API and the Raw Materials to manufacture
         Product in accordance with the terms and conditions of this Agreement.
         APG shall assume all responsibility and risk for the safekeeping,
         storage and handling of all API and Raw Materials.

2.5      Batch Testing; Certificate of Authenticity. APG shall test, or cause to
         be tested, in accordance with the Specifications, each batch of Product
         manufactured pursuant to this Agreement before delivery to Connetics.
         Prior to each shipment of Product, APG shall provide to Connetics a
         Certificate of Analysis attesting to the quality of each batch
         contained within the shipment, including review and approval by the
         appropriate quality control unit of all batch production and control
         records. APG shall maintain and provide Connetics with such
         documentation as may be required for compliance with FDA and other
         applicable regulations.

                                                                          PAGE 4

<PAGE>

2.6      Good Manufacturing Practice. APG shall manufacture, store and prepare
         all Products for shipping in accordance with cGMPs, in an FDA inspected
         facility, currently envisioned to be APG's facilities in Indiana,
         located at 1919 Superior Street, Elkhart, Indiana (formulation and
         compounding; in process testing; finished product testing) and 2825
         Middlebury Street, Elkhart, Indiana (fill and packaging). APG shall
         ensure that the housekeeping and maintenances of each facility complies
         with cGMP requirements. APG may not change manufacturing of Products to
         an alternate facility without first obtaining Connetics' written
         approval, including the approvals required pursuant to the Quality
         Agreement, such approval not to be unreasonably withheld.

2.7      DMF. APG shall maintain a DMF or like filing, suitable for APG's
         manufacture of Products, with the applicable regulatory agencies
         (including FDA) and shall ensure that its "active status" is
         maintained. APG shall use Commercially Reasonable Efforts to timely
         accomplish, and bear the costs of, preparing for regulatory inspection,
         approval and associated filings required for the manufacture of
         Connetics' Products. Connetics shall directly pay or reimburse APG for
         any fees and payments to such regulatory agencies required for such
         inspection, approval and associated filings (e.g., any FDA inspection
         fee); it is understood that Connetics is not responsible for any
         additional fees and payments related to the general operation of APG's
         business or facilities. APG will provide letter(s) granting Connetics
         and its designees the right of cross-reference to the DMF. APG reserves
         the right to cancel such letter(s) in case of termination of this
         Agreement.

2.8      Licenses. APG agrees that it shall, at its sole cost and expense,
         maintain any and all licenses, permits and consents necessary and/or
         required for APG to manufacture the Product and otherwise perform its
         obligations under this Agreement.

2.9      Inspections. Connetics has the right at any time during the term of
         this Agreement, upon reasonable prior notice and during reasonable
         business hours and without disruption to APG's business, to inspect
         APG's facility, and to make FDA-type inspections at its plant to
         satisfy itself that APG manufactures and documents the Product
         according to current cGMPs, consistent with FDA standards and
         requirements. Such inspections may only be made by individuals
         reasonably acceptable to APG. The provisions of this SECTION 2.9 are
         subject to the confidentiality provisions OF ARTICLE 7. Connetics shall
         be responsible for its costs of travel and accommodation for such
         inspections.

2.10     Changes to Specifications.

         (a)      If Connetics desires any material change to the Specifications
                  or manufacturing process, Connetics shall deliver, sixty (60)
                  days prior to the expected date of implementation, written
                  notice to APG specifying such change desired by Connetics, and
                  APG shall acknowledge in writing any such notice within thirty
                  (30) days after APG receives the notice; provided, however,
                  that the Specifications or process shall not be supplemented,
                  modified or amended in any respect without the prior written
                  agreement of the Parties. APG will use Commercially Reasonable
                  Efforts to implement changes within one hundred and

                                                                          PAGE 5

<PAGE>

                  twenty (120) days after APG's acknowledgement of such notice.
                  If Connetics requests a change to a Product Specification,
                  including the manufacturing process, and APG agrees that such
                  change is feasible, such change shall be incorporated within
                  the Product Specification pursuant to a written amendment to
                  this Agreement. Connetics shall be responsible for obtaining
                  any required FDA approval prior to implementation of such a
                  change at Connetics' cost.

         (b)      APG will communicate to Connetics in a timely manner any
                  change in the Product Specification, including the
                  manufacturing process, initiated by APG, and will obtain
                  Connetics' written approval by way of written amendment of
                  this Agreement incorporating such change within the Product
                  Specification prior to implementation of the change. No such
                  change may be instituted except in compliance with this
                  Agreement and the Quality Agreement. Connetics shall have the
                  option of obtaining, or having APG obtain any required FDA
                  approval or other regulatory approval prior to implementation
                  of such a change. APG may provide additional services in
                  conjunction with the manufacture of Products, such as
                  additional formulation, process development or stability
                  testing, at the request of Connetics and pursuant to
                  Connetics' purchase order, and all data and results from such
                  additional services shall be owned by Connetics and protected
                  as confidential under this Agreement.

2.11     Connetics Representative at APG. Connetics may, at Connetics' expense,
         place a company representative on-site at APG's manufacturing facility
         during the term of this Agreement. Subject to the following sentence,
         such representative shall have full access to all operations,
         documents, and records that specifically pertain to the manufacture of
         the Products. The Connetics Representative shall accept APG's
         procedures regulating external customer relationships (including GMP
         training, guarantee of confidentiality, and health procedures), and
         shall not materially disrupt APG's operations. Nothing in this SECTION
         2.11 shall be read to prevent APG from denying access to the Connetics
         Representative at any time when the confidentiality of another APG
         customer would be compromised by the presence of the Connetics
         Representative.

2.12     Equipment. Connetics has purchased the equipment listed on EXHIBIT D,
         all of which is to be kept at APG's facilities at 1919 Superior Street
         and 2825 Middlebury Street, Elkhart, Indiana. APG shall use the
         equipment solely in the manufacture and testing of Connetics' Products,
         and shall be responsible for maintaining and servicing the equipment.
         APG consents to the filing of any papers or documents necessary to
         secure Connetics' security interest in the equipment. Division 9 of the
         California Commercial Code shall govern the rights and obligations of
         the Parties relative to the security interests in the equipment.

                                   ARTICLE 2.5
                                   EXCLUSIVITY

2.5.1    Exclusivity. As consideration for the Payment, during the term of this
         Agreement, APG shall not engage in any new manufacturing or development
         activities for any aerosol

                                                                          PAGE 6

<PAGE>

         foam-based prescription dermatology product(s) for any other party
         without first obtaining Connetics' written consent, which consent can
         be withheld by Connetics for any reason and at its sole discretion. All
         manufacturing and/or development activities for aerosol foam-based
         prescription dermatology product(s) APG is engaged in for other parties
         as of the effective date of this Agreement are permitted and do not
         require Connetics' written consent.

2.5.2    Protection of Know-How. Whether or not APG engages in activities
         specified in SECTION 2.5.1, but especially in those instances when APG
         does engage in those activities, whether such activities are engaged in
         prior to or after the effective date of this Agreement, or engaged in
         with or without Connetics' consent, APG shall protect and keep
         confidential, pursuant to the provisions of ARTICLE 7, all of
         Connetics' know-how. Connetics' know-how shall include but not be
         limited to:

         (a)      the manufacturing plan, process and/or instructions;

         (b)      the Specifications;

         (c)      testing procedures;

         (d)      validation, verification, and/or certification protocols,
                  including preliminary data and results;

         (e)      stability runs and/or testing;

         (f)      equipment qualifications, validations and/or verifications
                  specific to the Products; and

         (g)      equipment layout for the equipment used to manufacture the
                  Products.

         Furthermore, during the preparation, manufacture and internal review
         following the manufacturing process for the Products, no third party or
         unauthorized person shall have access to the area in which the
         manufacturing process takes place. No third party or unauthorized
         person shall have access at any time to the equipment and machinery
         dedicated to the manufacture of the Products.

2.5.3    Acceleration upon Breach. If APG breaches the provisions of this
         ARTICLE 2.5 and Connetics does not terminate this Agreement pursuant to
         SECTION 10.2, then all remaining Annual Credits, shall be immediately
         accelerated and the remaining portion of the Payment that has not been
         credited to Connetics shall be applied 100% to all then-current and
         future Product orders and/or development work until fully credited to
         Connetics.

                                                                          PAGE 7

<PAGE>

                                    ARTICLE 3
                               PLANNING AND SUPPLY

3.1      Production. APG will produce Products to meet the mutually agreed upon
         forecasts, subject to the provisions of this ARTICLE 3. APG will keep
         Connetics reasonably informed of all scheduled production activity for
         the Products.

3.2      Termination of Obligation. APG's obligation to supply Product to
         Connetics shall terminate pursuant to the provisions of ARTICLE 10
         below.

3.3      Forecasts. Connetics shall provide APG with an annual forecast for
         budgeting and production planning purposes. Connetics shall also
         deliver to APG a monthly update during the first calendar week of each
         month, together with a summary of changes from the previous update.
         Forecasts shall include the amounts of each Product to be manufactured
         and supplied by APG and the expected timing for the delivery of each
         shipment during the forecast period.

3.4      Purchase Orders. Connetics will place written purchase orders directly
         or through its designated representatives with APG approximately twelve
         (12) weeks prior to requested shipment date, including the following
         details: number of units, requested shipping date, shipping
         instructions and Connetics' order reference number including the price
         calculated according to this Agreement. Each purchase order issued
         pursuant to this Agreement shall be governed by the terms and
         conditions of this Agreement, and shall override any conflicting
         provisions in any purchase order and any invoice or packing slip
         generated by APG with respect to the details set forth in this SECTION
         3.4.

3.5      Receipt and Acceptance by APG. APG shall promptly acknowledge its
         receipt of purchase orders and inform Connetics of the anticipated
         dates of manufacture and delivery of each Product presentation to
         Connetics. APG shall respond in writing as to its acceptance of each
         firm purchase order within fifteen (15) days of receipt of such order.
         Any portion of the order that exceeds the most recent corresponding
         twelve (12) month forecast (supplied pursuant to SECTION 3.3) by more
         than one hundred ten percent (110%) will be accepted at APG's
         discretion. Once a specified quantity, form and delivery date terms
         have been agreed to by the Parties in any purchase order placed
         pursuant to this SECTION 3.5, the purchase order may not be canceled by
         either Party except as provided in SECTION 3.10 or in SECTION 3.11
         below. Connetics acknowledges that the acceptance of a purchase order
         triggers the purchase of Unique Materials, as defined in Section 3.12.

3.6      Shipment; Delays. APG shall use Commercially Reasonable Efforts to ship
         Product to Connetics by the delivery date specified in the accepted
         purchase order. If APG believes there will be a significant delay in
         shipment of Finished Product beyond the delivery dates specified in any
         accepted purchase order, APG shall promptly inform Connetics of such
         expected delay and shall use Commercially Reasonable Efforts to
         minimize the delay.

                                                                          PAGE 8

<PAGE>

3.7      Change Orders. The time of delivery and quantities specified in a
         purchase order accepted by APG pursuant to SECTION 3.5 above shall be
         binding upon the Parties and may not be changed or canceled, except as
         provided in SECTIONS 3.9 AND 3.10 below.

3.8      Increased Demand. APG will use Commercially Reasonable Efforts to
         accommodate Connetics' requests for Units in excess of those reserved
         for Connetics; provided, however, that it shall not be a breach of this
         Agreement if APG, despite its Commercially Reasonable Efforts, is
         unable to supply quantities of Product to Connetics in excess of 110%
         of the annual forecast supplied pursuant to SECTION 3.3 for that year.

         3.9      Postponement of Manufacturing; Penalties.

         (a)      By Connetics. Connetics may postpone a purchase order for
                  production in accordance with the provisions in this Section.
                  Connetics may postpone each purchase order one time. In the
                  event of postponement pursuant to this SECTION 3.9, APG shall
                  use Commercially Reasonable Efforts to reschedule the
                  postponed order to a date agreeable to both Parties.
                  Regardless of the amount of notice, if Connetics does not
                  reschedule the Date of Manufacture to a date within forty-five
                  (45) calendar days of the originally scheduled date, the
                  Purchase Order shall be deemed cancelled, and Connetics shall
                  incur the penalties, if any, pursuant to SECTION 3.10.

         (b)      By APG.

                  (i)      APG shall use Commercially Reasonable Efforts to meet
                           the terms of a purchase order that it accepts, taking
                           into account mutually agreed upon forecasts under
                           SECTION 3.3, available plant capacity and timing of
                           its production.

                  (ii)     APG shall immediately notify Connetics if APG is
                           unable to fill any purchase order place by Connetics
                           pursuant to SECTION 3.4 for any reason, and advise
                           Connetics of the revised delivery date. Connetics
                           shall then have the option of terminating the
                           purchase order without obligation of payment or of
                           accepting the revised delivery date.

3.10     Cancellation of Purchase Orders; Penalties. Connetics may cancel a
         purchase order for production in accordance with the provisions in this
         Section. In addition to any charges for Unique Materials pursuant to
         SECTION 3.12, Connetics shall be assessed a charge for cancellation,
         determined according to the following schedule:

         (a)      If Connetics gives at least forty-five (45) calendar days
                  notice prior to the manufacturing date assigned by APG
                  pursuant to SECTION 3.5, there shall be no penalty for
                  cancellation.

         (b)      If Connetics gives less than forty-five (45) calendar days and
                  more than fourteen (14) days notice, APG may invoice Connetics
                  for, and Connetics shall be required to pay to APG an amount
                  equal to thirty percent (30%) of

                                                                          PAGE 9

<PAGE>

                  the amount owed under the purchase order, calculated in
                  accordance with EXHIBIT B; provided, however, that APG must
                  use Commercially Reasonable Efforts to reallocate the suite to
                  manufacture another product on the originally scheduled date,
                  and no charge shall be assessed to Connetics if such efforts
                  are successful.

         (c)      If Connetics gives fourteen (14) days or less notice, APG may
                  invoice Connetics for, and Connetics shall be required to pay
                  to APG an amount equal to, fifty percent (50%) of the amount
                  owed under the purchase order, calculated in accordance with
                  EXHIBIT B; provided, however, that APG must use Commercially
                  Reasonable Efforts to reallocate the suite to manufacture
                  another product on the originally scheduled date, and no
                  charge shall be assessed to Connetics if such efforts are
                  successful.

3.11     Shipment; Inspection; Rejection

         (a)      Shipment of Product. APG shall ship, or cause to be shipped at
                  Connetics' expense, the Product to Connetics or such
                  destination(s) as Connetics may designate in writing. Delivery
                  of Product to a common carrier authorized by Connetics shall
                  constitute delivery to Connetics, and risk of loss shall pass
                  to Connetics at that time. APG agrees to provide support to
                  assist Connetics to pursue any Product related claims it may
                  have against carriers, provided that Connetics shall reimburse
                  APG for any out-of-pocket expenses APG may incur in providing
                  such support. All invoices and other shipping documents shall
                  be sent by first class mail or by fax to Connetics' address
                  for notices under this Agreement, directed to the attention of
                  Controller.

         (b)      Non-Conforming Product. Connetics may reject any shipment of
                  Product that does not conform to the Manufacturing Standards,
                  subject to the terms of this Section and the Quality
                  Agreement. Except with respect to "hidden defects," within ten
                  (10) business days after APG's internal release of Product,
                  Connetics shall inspect the Product and notify APG whether it
                  will accept or reject the Product. If Connetics does not
                  notify APG of the non-conformity of such Product, the Product
                  shall be deemed to meet the Specifications, except for hidden
                  defects. No inspection under this Section shall relieve APG of
                  its obligations and warranties under this Agreement. If
                  Connetics rejects all or any part of any shipment of Product,
                  the procedures to be followed are:

                  (i)      Connetics shall submit to APG in writing any claim
                           that Product does not conform with the Specifications
                           or cGMPs, accompanied by a report of Connetics'
                           analysis (which analysis shall be conducted in good
                           faith) and a sample of the Product at issue,
                           explaining in reasonable detail the basis on which
                           the allegedly nonconforming Product does not meet the
                           Specifications. Once nonconformance is confirmed and
                           fault is determined to belong with APG pursuant to
                           the provisions of this SECTION 3.11(b), Connetics
                           shall not be obligated to pay for such nonconforming

                                                                         PAGE 10

<PAGE>

                           shipment of Product. Only those tests listed in the
                           Specifications may be used to demonstrate
                           nonconformance of Product.

                  (ii)     APG shall conduct its own analysis of the sample in
                           good faith within thirty (30) days after the receipt
                           by APG of the report and sample from Connetics, and
                           provide the results to Connetics.

                           (A)      If after APG's own analysis of the sample
                                    APG agrees with the claim of nonconformity,
                                    Connetics shall promptly inform APG if
                                    Connetics wishes to have APG replace the
                                    nonconforming Product with conforming
                                    Product. If Connetics wishes to receive such
                                    replacement Product, APG shall provide such
                                    replacement as soon as reasonably
                                    practicable thereafter, in which case
                                    Connetics shall be obligated to pay only for
                                    such replacement Product. Connetics shall
                                    not be obligated to pay for the
                                    nonconforming Product, and APG shall: (1)
                                    credit Connetics for the amount paid by
                                    Connetics to APG for the nonconforming
                                    Product if Connetics has already paid for
                                    such nonconforming Product or (2) cancel its
                                    invoice to Connetics for such nonconforming
                                    Product if Connetics has not yet paid for
                                    such nonconforming Product, and Connetics
                                    shall not be obligated to pay such canceled
                                    invoiced amount.

                           (B)      If, after its own analysis, APG does not
                                    agree with the claim of nonconformity or
                                    determines that Connetics is responsible for
                                    the nonconformity, such Product shall be
                                    tested for conformance with the applicable
                                    Specifications by an independent third party
                                    testing laboratory mutually acceptable to
                                    both parties. The independent analysis shall
                                    be binding on both Parties solely for the
                                    purpose of determining whether such Product
                                    may be rightfully rejected.

                  (iii)    After a final determination that the Product shipment
                           is nonconforming, and if APG is responsible for the
                           nonconformity, Connetics shall return or destroy it
                           at APG's request and cost in the most cost effective
                           and environmentally safe and appropriate manner
                           available, consistent with federal, state and local
                           laws and regulations.

                  (iv)     If conforming Product supplied under this Agreement
                           becomes nonconforming or unsuitable at no fault of
                           APG, Connetics will remain obligated to pay APG for
                           such Product. At APG's request, Connetics shall
                           return such unsuitable Product to APG. Otherwise,
                           Connetics shall destroy it in the most
                           environmentally safe and

                                                                         PAGE 11

<PAGE>

                           appropriate manner available, consistent with
                           federal, state and local laws and regulations.

         (c)      Hidden Defects. For purposes of this Agreement, "hidden
                  defect" means a defect in the Product not discovered by
                  Connetics during its testing of the Product in accordance with
                  generally accepted practices in the pharmaceutical industry
                  and which would not be a defect reasonably expected to be
                  discovered in accordance with such testing. In the case of a
                  hidden defect, Connetics shall have the right to request that
                  APG provide to Connetics, within 30 days after APG receives
                  notice of the hidden defect, Product that meets the
                  Specifications or to promptly provide Connetics with full
                  credit for the Purchase Price paid by Connetics for the
                  returned Product.

         (d)      Notwithstanding the other provisions of this SECTION 3.11,
                  Connetics shall have no right to reject any Product that fails
                  to conform with the Manufacturing Standards if the
                  nonconformance is attributable to (i) events outside of APG's
                  control that occurred after delivery to a common carrier, or
                  (ii) processes, procedures or Product components specified or
                  approved in writing by Connetics in the Specifications or
                  otherwise, provided that APG followed or used such processes,
                  procedures and Product components materially in accordance
                  with the Specifications.

3.12     Unique Materials. Connetics shall reimburse APG for its actual costs
         expended for the purchase of "Unique Materials" (i.e., certain raw
         materials, artwork, printed cans, labels, cartons and special valves)
         purchased by APG expressly to meet its performance obligations under
         this Agreement in reliance upon a firm purchase order pursuant to
         SECTION 3.4 and which later are made obsolete, or to the extent that
         such Unique Materials remain on hand at the expiration of this
         Agreement as provided under SECTION 10.1. For purposes of this Section,
         material is obsolete if it cannot be incorporated into the Product due
         to changes mandated by a Regulatory Authority, changes directed by
         Connetics, or Connetics-mandated cancellation or postponement. Once
         material becomes obsolete, APG may invoice Connetics from time to time
         for APG's cost to acquire such obsolete material, which invoices shall
         identify the material in question and shall be accompanied by a
         reasonably detailed statement of the cause of such obsolescence and a
         certification that APG has disposed of such materials in accordance
         with the terms of this Agreement.

3.13     Risk of Loss. Risk of loss of Product shall be with APG until delivery
         of Product to a common carrier pursuant to SECTION 3.11 of this
         Agreement.

3.14     Insurance. APG shall at its own expense obtain and maintain workers'
         compensation and comprehensive general liability insurance with respect
         to performance under this Agreement, in amounts that APG determines to
         be reasonable, but in no event less than $5,000,000.00.

                                                                         PAGE 12

<PAGE>

                                    ARTICLE 4
                             PRICE AND PAYMENT TERMS

4.1      Price for Connetics' Products. The price for Connetics' Products shall
         be the actual cost of Raw Materials and Components, plus the
         Manufacturing Fee. The Manufacturing Fee shall be a per Unit fee for
         Products in amounts to be agreed per Unit for each Product and for each
         size or formulation. As of the Effective Date, the agreed upon
         Manufacturing Fee for each Product shall be set forth in the document
         attached as EXHIBIT B to this Agreement, which Exhibit may be amended
         from time to time by the mutual written agreement of the Parties to add
         or delete Products and/or size or formulation of Products. The
         Manufacturing Fee and Product Rebate set forth in Exhibit B for the
         Products listed in Exhibit A shall not be increased or decreased during
         the Initial Term of this Agreement, as defined in SECTION 10.1.

4.2      Invoices. APG shall submit to Connetics an invoice five (5) days after
         APG's internal release of Product. Connetics shall make payment of each
         invoice within thirty (30) days after receipt by Connetics. If within
         thirty (30) days after the delivery of Product and the accompanying
         Certificate of Analysis to Connetics, Connetics demonstrates
         non-conformance under SECTION 3.11 and APG agrees with such finding,
         Connetics shall not be obligated to pay for such non-conforming
         shipment.

4.3      Currency. Amounts due to APG under this Agreement are payable in U.S.
         Dollars.

4.4      Pre-payment. APG may only use the Payment to reduce current debts it
         has with certain of its vendors, which vendors APG will identify in
         writing prior to receiving the Payment. Upon the execution of this
         Agreement by the Parties, and receipt by Connetics of the list of
         vendors specified in the previous sentence, Connetics shall pay APG the
         Payment.

4.5      Annual Credit. APG will repay the Payment by applying a credit to
         current and future commercial and samples Product orders and any future
         development work for Connetics at the rate of [*] (the "Annual
         Credit"), subject to acceleration as provided for in this Agreement.
         The Annual Credit will be applied each year as a [*] of Product orders
         and/or development work. The first Annual Credit, unless otherwise
         accelerated, shall be applied to all then-open and future Product
         orders and/or development work starting on the date that APG gets loan
         funding on the New Loan. All subsequent Annual Credits, unless
         otherwise accelerated, shall be applied to all open and future Product
         orders and/or development work each year starting on the anniversary
         date of this Agreement until fully credited to Connetics.

4.6      Acceleration. If APG does not obtain loan funding on the New Loan as
         well as complete [*] subject to an additional 30 day grace period if
         needed, then all remaining Annual Credits shall be immediately
         accelerated and the remaining portion of the Payment that has not yet
         been credited to Connetics shall be applied 100% to all then-current
         and future Product orders and/or development work until fully credited
         to Connetics.

                                                                         PAGE 13

[*]  Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to
the omitted portions.
<PAGE>

                                   ARTICLE 4.5
                                   COLLATERAL

After APG obtains funding on the New Loan, APG shall grant Connetics a security
interest in all current and future API and Raw Materials (collectively the
"Collateral"). The security arrangement will be evidenced by a security
agreement and shall be perfected by the filing of financing statements (UCC-1)
with applicable authorities. Financing statements (UCC-1) shall be filed only
after APG obtains funding on the New Loan. Except for the lender funding the New
Loan, APG shall obtain subordination agreements from other lenders if any then
existing lender has a senior security interest in the Collateral, such that
Connetics' security interest shall be senior to all others.

                                    ARTICLE 5
                                   WARRANTIES

5.1      Quality. Each shipment of Product under this Agreement shall have been
         manufactured in accordance with U.S. cGMPs in a duly licensed facility
         and shall have been subject to a quality control inspection by
         Connetics in accordance with the Specifications and the Quality
         Agreement. APG shall number each Product shipment with a vendor lot
         number that is traceable to Raw Materials used to manufacture such
         Product.

5.2      cGMP employees. Within 90 days after APG obtains loan funding on the
         New Loan, APG agrees to hire, with Connetics' assistance and consent,
         two new cGMP employees to work at APG on cGMP matters. If the positions
         are not filled within 90 days after APG obtains a loan commitment on
         the New Loan, then all remaining Annual Credits shall all be
         immediately accelerated and the remaining portion of the Payment that
         has not yet been credited to Connetics shall be applied 100% to all
         then-current and future Product orders and/or development work until
         fully credited to Connetics.

5.3      Representations and Warranties.

         (a)      APG warrants that Product delivered to Connetics pursuant to
                  this Agreement shall, at the time of delivery:

                  (i)      have been manufactured, filled, packaged, and shipped
                           in accordance with all applicable laws, rules,
                           regulations or requirements;

                  (ii)     have been stored in accordance with all laws, rules,
                           regulations or requirements relating to the handling
                           of hazardous materials;

                  (iii)    have been manufactured, filled, packaged and stored
                           in accordance with, and will conform to, the
                           Specifications;

                                                                         PAGE 14

<PAGE>

                  (iv)     will be free from defects in material, manufacturing
                           and workmanship for the shelf life of the Product as
                           set forth in the Specifications; and

                  (v)      not be adulterated or misbranded within the meaning
                           of the Federal Food, Drug and Cosmetic Act (the
                           "Act") as amended, or within the meaning of any
                           applicable state or municipal law in which the
                           definitions of adulteration and misbranding are
                           substantially the same as those contained in the Act,
                           as the Act and such laws are constituted and
                           effective at the time of delivery.

         (b)      Licensing. APG represents and warrants that it has obtained
                  and will maintain on a current basis and will comply with all
                  licenses, permits and approvals of applicable governmental
                  agencies as may be required to manufacture, test and store the
                  Product pursuant to this Agreement and perform its other
                  obligations under this Agreement. APG shall be responsible for
                  obtaining and maintaining licenses and permits for
                  manufacture, testing and storage of the Product and ensuring
                  that its facilities used in the manufacture of the Product
                  meet cGMPs in all respects.

         (c)      Compliance with Laws. APG represents and warrants that it
                  shall comply with all federal, state, local and foreign laws,
                  regulations and other requirements applicable to the
                  manufacture, testing and storage of the Product and the
                  performance of APG's obligations under this Agreement. APG
                  shall have sole responsibility for adopting and enforcing
                  safety procedures for the handling and manufacture of the
                  Product at its facilities and the proper handling and proper
                  disposal of waste relating to the Product.

5.4      Limitations; Indemnification.

         (a)      Limitations on Warranty. The warranty furnished in SECTION
                  5.2(b) shall not apply to defects caused by accident or
                  willful damage, abuse, misuse, neglect, improper testing,
                  handling, storage or use after delivery by APG of the Product
                  in question to Connetics.

         (b)      No Implied Representations; Warranties or Conditions. EXCEPT
                  AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER APG
                  NOR CONNETICS MAKES ANY REPRESENTATIONS OR WARRANTIES AND
                  THERE ARE NO CONDITIONS, EXPRESS OR IMPLIED, STATUTORY OR
                  OTHERWISE, WITH RESPECT TO PRODUCT SUPPLIED UNDER THIS
                  AGREEMENT, INCLUDING, WITHOUT LIMITATION, ANY REPRESENTATIONS,
                  WARRANTIES OR CONDITIONS WITH RESPECT TO NONINFRINGEMENT,
                  MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF SUCH
                  PRODUCT, OR ARISING FROM A COURSE OF DEALING OR USAGE OF TRADE
                  PRACTICE.

         (c)      Limitation of Liability. EXCEPT FOR ANY LOSS, LIABILITY,
                  DAMAGE OR OBLIGATION ARISING OUT OF OR RELATING TO THE
                  DISCLOSURE OF

                                                                         PAGE 15

<PAGE>

                  CONFIDENTIAL INFORMATION PURSUANT TO ARTICLE 7 OR AS OTHERWISE
                  EXPRESSLY SET FORTH IN THIS AGREEMENT, IN NO EVENT SHALL
                  EITHER PARTY HAVE ANY LIABILITY TO THE OTHER PARTY OR ANY
                  OTHER THIRD PARTY FOR ANY LOST OPPORTUNITY, COSTS OF
                  PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES, OR FOR ANY
                  INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR SPECIAL
                  DAMAGES ARISING OUT OF THIS AGREEMENT, UNDER ANY CAUSE OF
                  ACTION OR THEORY OF LIABILITY (INCLUDING NEGLIGENCE), AND
                  WHETHER OR NOT SUCH PARTY TO THIS AGREEMENT HAS BEEN ADVISED
                  OF THE POSSIBILITY OF SUCH DAMAGE. THESE LIMITATIONS SHALL
                  APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY
                  LIMITED REMEDY.

                                    ARTICLE 6
                               TECHNOLOGY TRANSFER

6.1      Technology Transfer by Connetics. APG acknowledges that from
         time-to-time for business reasons unrelated to APG's performance,
         Connetics may wish to qualify one or more additional manufacturing
         sources for Product. Without derogating from APG's rights under this
         Agreement, if Connetics wishes to qualify an additional source, APG
         shall cooperate with Connetics in transferring the manufacturing
         technology and know-how to another entity ("Connetics Technology
         Transfer"). For purposes of this ARTICLE 6, the term "cooperation" may
         include providing documentation, Raw Materials or Components, samples
         of Product, or other information at Connetics' request, and means not
         taking any action to hinder the qualification of the second source
         (e.g., by delaying a response to Connetics' requests for assistance).
         Connetics shall reimburse APG for its time and materials expended to
         cooperate with Connetics in connection with the Connetics Technology
         Transfer.

6.2      Technology Transfer by APG. If during the period that any portion of
         the Payment has not been fully credited to Connetics, APG stops doing
         business as a going concern Connetics has the right to use APG
         facilities, equipment, manufacturing technology and know-how ("APG
         Technology Transfer") to manufacture Connetics' Products subject to any
         of APG's lenders' senior rights and approvals. In such event APG shall
         cooperate with Connetics in all respects with the APG Technology
         Transfer. Connetics' rights to the APG Technology Transfer shall cease
         when the Payment has been fully credited to Connetics.

                                    ARTICLE 7
                                 CONFIDENTIALITY

7.1      Confidentiality.

         (a)      Confidential Information. The Parties acknowledge that by
                  reason of their relationship to each other under this
                  Agreement, each will have access to certain information and
                  materials concerning the other's business, plans, trade
                  secrets, customers (including, but not limited to, customer
                  lists), technology, and/or

                                                                         PAGE 16

<PAGE>

                  products that is confidential and of substantial value to that
                  Party, which value would be impaired if such information were
                  disclosed to Third Parties ("CONFIDENTIAL INFORMATION"). Each
                  Party agrees that it will not use in any way other than
                  expressly authorized or contemplated under this Agreement, nor
                  disclose to any third party, any such Confidential Information
                  revealed to it by the other Party (except that Confidential
                  Information may be disclosed, as required for the purposes of
                  this Agreement, to any Regulatory Authority, an Affiliate,
                  assignee, distributor, consultant or third party contractor or
                  research and development organization under similar written
                  obligations of non-disclosure and non-use), and will take
                  every reasonable precaution to protect the confidentiality of
                  such information and with no less restrictive precautions than
                  it takes to protect its own confidential information. If
                  Confidential Information is required to be disclosed in
                  response to a valid order by a court, Regulatory Authority or
                  other government body of competent jurisdiction, or if
                  otherwise required to be disclosed by law, or if necessary to
                  establish the rights of either Party under this Agreement, the
                  receiving Party shall use Commercially Reasonable Efforts to
                  provide the disclosing Party with advance notice of such
                  required disclosure to give the disclosing Party sufficient
                  time to seek a protective order or other protective measures,
                  if any are available, for such Confidential Information.

         (b)      Exceptions. For purposes of this Agreement, information shall
                  be deemed Confidential Information if such information, by its
                  nature or due to the context within which it is disclosed, is
                  obviously intended by the disclosing Party to be kept
                  confidential even if not identified as such in writing or with
                  legends or other markings. The person disclosing Confidential
                  Information shall endeavor to confirm verbally disclosed
                  Information as "CONFIDENTIAL" in writing, given the
                  understanding that failure to do so does not constitute a
                  designation of non-confidentiality, particularly when the
                  confidential nature is apparent from context and subject
                  matter. Upon request by either Party, the other Party will
                  advise whether or not it considers any particular information
                  or materials to be Confidential Information. Confidential
                  Information does not include information, technical data or
                  know-how that:

                  (i)      is or becomes publicly available through no fault of
                           the receiving Party or its individual employees,
                           agents or members amounting to a breach of this
                           Agreement;

                  (ii)     is lawfully obtained on a non-confidential basis by
                           the receiving Party from a third party who is not
                           obligated to retain such information in confidence;

                  (iii)    the receiving Party can demonstrate, by competent
                           evidence, was known to it or any of its Affiliates
                           from a source other than the disclosing Party or any
                           of its Affiliates prior to the disclosure under this
                           Agreement;

                                                                         PAGE 17

<PAGE>

                  (iv)     the receiving Party can demonstrate by its written
                           records is independently developed by employees of
                           the receiving Party or an Affiliate of the receiving
                           Party, which employees were neither privy to nor had
                           access to the Confidential Information and which is
                           developed without use in any way of the Confidential
                           Information;

                  (v)      must be disclosed to governmental agencies, provided
                           that: (A) this exception shall only apply to
                           disclosure to such agencies, and not to any other
                           person or entity; and (B) the disclosing Party shall
                           (1) provide the other Party with prompt notice
                           (including copies of all written requests or demands)
                           of any proposed disclosure to any governmental
                           agency, with an explanation of the Confidential
                           Information of the other Party to be disclosed; and
                           (2) cooperate in any lawful effort by the other Party
                           to prevent, limit or restrict disclosure of its
                           Confidential Information to such government agency.

7.2      Remedy. If either Party breaches any of its obligations with respect to
         this ARTICLE 7, or if such a breach is likely to occur, the other Party
         shall be entitled to seek equitable relief, including specific
         performance or an injunction, in addition to any other rights or
         remedies, including money damages, provided by law, without posting a
         bond.

7.3      Agreement Terms. Subject to SECTION 15.2 and the exclusions set forth
         in SECTION 7.1(b), the Parties shall treat the terms and conditions of
         this Agreement as Confidential Information; provided, however, after
         written notification to the other Party, each Party may disclose the
         existence of this Agreement and the material terms and conditions of
         this Agreement under circumstances that reasonably ensure the
         confidentiality thereof to: (a) any government or regulatory
         authorities, including without limitation the United States Security
         and Exchange Commission pursuant to applicable law (excluding, to the
         extent legally permitted, disclosure of financial terms in any publicly
         available versions of information so disclosed), (b) its legal
         representatives, advisors and prospective investors, and (c) to
         Connetics' licensors to the extent required for compliance with
         Connetics' obligations under third party licenses.

7.4      Return of Confidential Information. Within ten (10) days following the
         termination of any agreement between the Parties with respect to the
         subject matter the receiving Party agrees to promptly return all
         tangible items relating to the Confidential Information, including all
         written material, photographs, models, compounds, compositions and the
         like made available or supplied by the disclosing Party to receiving
         Party, and all copies thereof, upon the request of the disclosing
         Party, except such records as may be required to be kept for FDA or
         other government regulatory compliance. Recipient further agrees to
         identify those persons to whom the Confidential Information that is the
         subject of this Agreement was disclosed upon request of the disclosing
         Party.

                                                                         PAGE 18

<PAGE>

7.5      Inside Information. APG understands that Confidential Information may
         constitute "inside information" of Connetics for securities purposes
         and agrees to refrain from any unlawful disclosure, trading or other
         improper use of such information.

                                    ARTICLE 8
                                   ASSIGNMENT

8.1      Assignment by APG. APG shall have no right or authority to assign the
         Agreement or any portion of the Agreement, to sublet or subcontract in
         whole or in part, or otherwise delegate its performance under this
         Agreement, without Connetics' prior written consent, which consent
         shall not unreasonably be withheld. No assignment shall be effective
         until the assignee shall have unconditionally assumed in writing all of
         the assignor's obligations under this Agreement and a written notice of
         such assignment is given to Connetics. Notwithstanding the foregoing,
         nothing in this Agreement shall prohibit APG from assigning this
         Agreement to any Affiliate of APG that may from time to time own or
         operate the Indiana facility or any other facility to which APG may
         move its manufacturing operations. No such assignment shall relieve APG
         of primary liability for the performance of its obligations under this
         Agreement.

8.2      Assignment by Connetics. Connetics may assign this Agreement, provided
         prior reasonable written notice has been given to APG. APG agrees that
         if this Agreement is assigned to any third party or Affiliate, all the
         terms and conditions of this Agreement shall continue between such
         third party or Affiliate and APG with the same force and effect as if
         said Agreement had been made with such third party or Affiliate in the
         first instance, provided that no such assignment shall relieve
         Connetics of primary liability for the performance of its obligations
         under this Agreement.

8.3      Binding Effect and Assignment. When duly assigned in accordance with
         this ARTICLE 8, this Agreement shall be binding upon and inure to the
         benefit of the assignee. Any attempted assignment contrary to the
         provisions of this ARTICLE 8 shall be deemed ineffective, and the
         non-assigning Party shall have the right to terminate this Agreement,
         with the effect described in SECTION 10.2.

                                    ARTICLE 9
                                  FORCE MAJEURE

Neither Party shall be considered in default of performance of its obligations
under this Agreement, except any obligation under this Agreement to make
payments or apply credits when due, to the extent that performance of such
obligations is delayed by contingencies or causes beyond the reasonable control
and not caused by the negligence or willful misconduct of such Party, including
but not limited to strike, fire, flood, earthquake, windstorm, governmental acts
or orders or restrictions, or force majeure, to the extent that the failure to
perform is beyond the reasonable control of the nonperforming Party, if the
Party affected shall give prompt written notice of any such cause to the other
Party. The Party giving such notice shall thereupon be excused from performance
of its obligations under this Agreement for the period of time that the

                                                                         PAGE 19

<PAGE>

condition constituting force majeure continues and the non-performing Party uses
good faith diligent efforts to mitigate, avoid or end such delay as soon as
practicable.

                                   ARTICLE 10
                              TERM AND TERMINATION

10.1     Term. Subject to the rights to terminate sooner under this Article 10,
         this Agreement shall expire on May 1, 2008 (the "Initial Term"), after
         which this Agreement may be renewed for successive periods of one or
         more calendar year(s) each, by written agreement of the Parties.

10.2     Termination for Material Breach. Either Party may terminate this
         Agreement upon written notice if the other Party has breached any of
         its material obligations under this Agreement, and (a) such breach has
         not been cured within 60 days after written notice of the breach, or
         (b) if a plan, reasonably acceptable to the non-breaching Party, is not
         implemented to cure as soon as practicable after notice of the breach

10.3     Termination upon Insolvency. Either Party may, in addition to any other
         remedies available to it by law or in equity, terminate this Agreement
         immediately by written notice to the other Party upon (i) the filing by
         the other Party of a voluntary petition in bankruptcy or seeking
         reorganization, liquidation, dissolution, winding-up, arrangement,
         composition or readjustment of its debts or any other relief under any
         bankruptcy, insolvency, reorganization or other similar act or law of
         any jurisdiction now or hereafter in effect, (ii) the filing against
         such other Party of an involuntary petition in bankruptcy which is not
         dismissed within 60 days, (iii) the appointment of a receiver or
         trustee of any of such other Party's property if such appointment is
         not vacated within 60 days, (iv) the adjudication of such other Party
         as insolvent, or (v) the assignment of such other Party's property for
         the benefit of its creditors (collectively, "Insolvency"). In the event
         of an Insolvency, if the Agreement is not terminated, then all
         remaining Annual Credits shall be immediately accelerated and the
         remaining portion of the Payment that has not yet been credited to
         Connetics shall be applied 100% to all then-current and future Product
         orders and/or development work until fully credited to Connetics.

10.4     Termination for Force Majeure. Either Party may terminate this
         Agreement upon thirty (30) days written prior notice in the event of
         the other Party's inability to substantially perform its obligations
         under this Agreement for more than one hundred eighty (180) days due to
         an event of force majeure as described in SECTION 9.1.

10.5     Payment upon Termination. If the Agreement is terminated pursuant to
         SECTION 10.2, SECTION 10.3 or SECTION 10.4, then all remaining Annual
         Credits shall be immediately accelerated and the remaining portion of
         the Payment that has not yet been credited to Connetics shall be
         immediately due and payable to Connetics.

10.6     Termination without Cause. After the Payment has been fully credited to
         Connetics, either Party may terminate this Agreement upon twelve (12)
         months' written notice.

                                                                         PAGE 20

<PAGE>

10.7     Accrued Liabilities. The termination of this Agreement for any reason
         shall not discharge either Party's liability for obligations incurred
         under this Agreement and amounts unpaid at the time of such
         termination. Connetics shall be liable to pay APG for any Product, work
         in progress and materials purchased by APG, less any remaining portion
         of the Payment that has not been credited to Connetics, to fulfill its
         obligations under this Agreement, provided however that APG shall make
         all Commercially Reasonable Efforts to mitigate its damages under such
         circumstances.

10.8     Return and Disposition of Property. Upon the termination of this
         Agreement for any reason, each Party shall return to the other Party or
         its designee all of such other Party's property, including, but not
         limited to, all proprietary information, in its possession. To the
         extent required by law or to comply with such Party's continuing
         obligations under this Agreement, each Party may keep a single copy of
         tangible property belonging to the other Party. APG shall dispose of
         all bulk active ingredients, raw materials, containers, and Labeling
         not necessary to complete work in progress at Connetics' expense, less
         any remaining portion of the Payment that has not been credited to
         Connetics, in accordance with Connetics' reasonable instructions.

10.9     Reversion of Rights. Upon the termination of this Agreement for any
         reason, APG shall have no further rights to manufacture under
         Connetics' patents, and all rights, title or interest in Connetics'
         technology shall revert automatically to Connetics without the need for
         further action.

                                   ARTICLE 11
                                 INDEMNIFICATION

11.1     Indemnification by APG. APG shall indemnify Connetics, its Affiliates
         and their respective directors, officers, employees and agents, and
         defend and hold each of them harmless, from and against any and all
         suits, losses, actions, demands, investigations, claims, damages,
         liabilities, costs and expenses (including, without limitation,
         reasonable attorneys' fees and expenses) (collectively, "LOSSES")
         brought by third parties arising from or occurring as a result of:

         (a)      a nonconformity of Product with the warranties under SECTIONS
                  5.1 and 5.2 except for any damages attributable to the
                  negligence of Connetics, its employees or agents;

         (b)      APG's failure to comply with the Specifications;

         (c)      any willful act or omission or negligence of APG or its
                  employees, agents or other contractors in the manufacturing
                  and testing of the Product; or

         (d)      APG's failure to comply with the Act and the regulations under
                  the Act in the production of Product.

                                                                         PAGE 21

<PAGE>

         (e)      any breach (or alleged breach) by APG of its representations,
                  warranties, or material obligations under this Agreement;

         (f)      the manufacture or the storage of the Product prior to the
                  date of shipment of Product to Connetics by APG or its
                  Affiliates,

         all except to the extent caused by the negligence or willful misconduct
         of Connetics or its officers, agents, employees, Affiliates,
         sublicensees or customers.

11.2     Indemnification by Connetics. Connetics shall indemnify APG, its
         Affiliates and their respective directors, officers, employees and
         agents, and defend and save each of them harmless, from and against any
         and all Losses brought by third parties arising from or occurring as a
         result of:

         (a)      failure by Connetics to comply with the Food Drug and Cosmetic
                  Act and the regulations under the Act;

         (b)      the handling or other use of the Product including by end
                  users;

         (c)      any willful act or omission or negligence of Connetics or its
                  employees, agents or other contractors

         (d)      any breach (or alleged breach) by Connetics of its
                  representations, warranties, or material obligations under
                  this Agreement;

         (e)      the manufacture by Connetics or third parties contracted by
                  Connetics, or the storage of Product after the date of
                  shipment of Product to Connetics by APG or its Affiliates,

         all except to the extent caused by the negligence or willful misconduct
         of APG or its officers, agents, employees, Affiliates, sublicensees or
         customers.

11.3     Patent Indemnification. Connetics shall indemnify, defend, and hold APG
         and its employees, servants and agents harmless from and against any
         and all claims, demands, actions, suits, losses, damages, costs,
         expenses (including reasonable attorney's fees), and liabilities which
         APG may incur, suffer or be required to pay by reason of any patent
         infringement suit brought against APG because of APG's manufacture of
         Product to the extent that the alleged infringement arose out of or
         related to APG's use of processes, compounds or other products the
         rights to which are claimed to be owned by Connetics.

11.4     Process. If either Party expects to seek indemnification from the other
         pursuant to the provisions of this ARTICLE 11, it shall promptly give
         notice to the indemnifying Party of any such Claim. The indemnifying
         Party shall have the right to control the defense of such Claim and the
         indemnified Party shall cooperate with the indemnifying Party in the
         defense of such Claim. The indemnifying Party shall have the right to
         settle or compromise any claim against the other Party without the
         consent of the other Party, provided that the terms of the settlement:

                                                                         PAGE 22

<PAGE>

         (a)      provide for the unconditional release of the Party being
                  indemnified;

         (b)      require the payment of compensatory monetary damages only by
                  the indemnifying Party; and

         (c)      expressly states that neither the fact of settlement nor the
                  settlement agreement shall constitute, or be construed or
                  interpreted as, an admission by the Party being indemnified of
                  any issue, fact, allegation or any other aspect of the claim
                  being settled.

         The Party being indemnified shall not pay or voluntarily permit the
         determination of any liability which is subject to any such action
         while the indemnifying Party is negotiating the settlement thereof or
         contesting the matter, except with the prior written consent of the
         indemnifying Party, which consent shall not be unreasonably withheld or
         delayed.

                                    ARTICLE 12
                            AUDIT RIGHTS; INSPECTIONS

12.1     Inspections. Connetics, upon its own discretion and at its own cost and
         expense, is entitled during ordinary business hours and at dates
         acceptable to APG to inspect or to have inspected, APG's plant and
         procedures used for manufacture and storage of the Products. Such
         inspections shall not materially disrupt APG's business for other
         customers.

12.2     Books and Records. APG agrees to maintain and cause its Affiliates to
         maintain complete and accurate books and records of account so as to
         enable Connetics to verify amounts due and payable under this
         Agreement. In particular, APG shall preserve and maintain all such
         records and accounts required for audit for a period of four (4) years
         after the calendar quarter for which the record applies.

12.3     Audit of APG's Records. During the term of this Agreement, Connetics
         shall have the right upon four (4) weeks notice to APG to have an
         independent certified public accountant, selected by Connetics and
         reasonably acceptable to APG, audit APG's records relating specifically
         to the Products during normal business hours; provided, however, that
         such audit shall not take place more frequently than once a year and
         shall not cover records for more than the preceding four (4) years.

12.4     Government Inspection. APG agrees to advise Connetics by telephone and
         facsimile immediately of any proposed or announced visit or inspection,
         and as soon as possible but in any case within twenty-four (24) hours
         of any unannounced visit or inspection, by any Regulatory Authority of
         any facilities used by APG in the performance of its obligations under
         this Agreement. APG shall provide Connetics with a reasonable
         description of each such visit or inspection promptly (but in no event
         later than five [5] calendar days) thereafter, and with copies of any
         letters, reports or other documents (including Form 483's) issued by
         any such authorities that relate to the Products, or such facilities,
         processes or procedures. Connetics may review APG's responses to any
         such reports and communications, and if practicable, and, insofar as
         timely received, Connetics'

                                                                         PAGE 23

<PAGE>

         reasonable views and requests shall be taken into account prior to
         submission of such reports and communications to the relevant
         Regulatory Authority.

                                   ARTICLE 13
                                    DISPUTES

13.1     Arbitration. If the Parties' are unable to settle amicably any claim,
         dispute, controversy or difference arising out of or in relation to or
         in connection with this Agreement or for breach of this Agreement
         through consultation and negotiation in good faith and a spirit of
         mutual cooperation, then the dispute shall be resolved through binding
         arbitration in accordance with the rules of the American Arbitration
         Association then in effect. Judgment upon the award rendered by the
         arbitrators may be entered in any court having jurisdiction thereof. In
         any arbitration pursuant to this section, the award shall be rendered
         by a majority of the members of a board of arbitration consisting of
         three members, one being appointed by each Party and the third being
         appointed by mutual agreement of the two arbitrators appointed by the
         parties. The place of arbitration shall be Palo Alto, California.

13.2     Waiver of Trial by Jury. If the Parties fail to resolve a dispute
         through negotiation or arbitration in accordance with SECTION 13.1,
         each Party shall have the right to pursue any of the remedies legally
         available to resolve the dispute; provided, however, that the Parties
         expressly waive any right to a jury trial in any legal proceedings
         under this ARTICLE 13.

13.3     Governing Law. This Agreement shall be governed, controlled,
         interpreted and defined by and under the laws of the State of
         California and the United States without regard to that body of law
         known as conflicts of law; provided that issues relating to the
         validity and enforceability of patents shall be governed by the laws of
         the jurisdiction by which such patent was granted.

                                   ARTICLE 14
                                     NOTICES

Any notice required or permitted by this Agreement shall be in writing and shall
be sent by prepaid registered or certified mail, return receipt requested; by
facsimile; by internationally recognized courier; or by personal delivery, in
each case addressed to the other Party at the address below or at such other
address for which such Party gives notice under this Agreement.

         If to Connetics, at:

                  Connetics Corporation
                  Attn: President and Chief Executive Officer
                  3290 West Bayshore Road
                  Palo Alto, California 94303

                                                                         PAGE 24

<PAGE>

         If to APG, at:

                  Accra Pac Group
                  Attn:  Chief Executive Officer
                  1919 Superior Street
                  Elkhart, Indiana 46516
                  With a copy to:  President

Such notice shall be deemed to have been given when delivered or, if delivery is
not accomplished by some fault of the addressee, when tendered. Either Party may
change its address for notice by delivering a written notice of the new address
in accordance with this Article.

                                   ARTICLE 15
                             NATURE OF RELATIONSHIP

15.1     No Agency; Independent Contractor. Each Party is and shall be
         considered to be an independent contractor of the other Party. Neither
         Party shall be the legal agent of the other for any purpose whatsoever
         and neither Party has any right or authority to make or underwrite any
         promise, warranty or representation, to execute any contract or
         otherwise to assume any obligation or responsibility in the name of or
         on behalf of the other Party. Neither Party shall be bound by or liable
         to any third persons for any act or for any obligation or debt incurred
         by the other toward such third party, except to the extent specifically
         agreed to in writing by the Party so to be bound.

15.2     Public Statements. The Parties shall endeavor to provide courtesy
         copies of any public announcements concerning the relationship created
         by this Agreement. Neither Party shall make any representations
         concerning the other without the prior consent from the other Party.
         Notwithstanding the foregoing, each Party consents to references to it
         in reports or documents or other disclosures sent to stockholders or
         filed with or submitted to any governmental authority or stock
         exchange. Except for such disclosure as is required by applicable law
         and/or stock exchange regulation, neither Party shall make any
         announcement, news release, public statement, publication or
         presentation relating to the existence of this Agreement or the
         arrangements referred to in this Agreement without first notifying the
         other Party.

15.3     No License. Nothing in this Agreement, including the original transfer
         of technical information from Connetics to APG, shall constitute any
         grant, option or license to APG under any patent or other rights now or
         hereafter held by Connetics.

                                                                         PAGE 25

<PAGE>

                                   ARTICLE 16
                              ADDITIONAL PROVISIONS

16.1     Headings. Article and section headings contained in this Agreement are
         included for convenience of reference only and shall not affect in any
         way the meaning or interpretation of this Agreement.

16.2     Partial Invalidity. If any provision of this Agreement is held to be
         invalid, illegal, or unenforceable by a court of competent
         jurisdiction, then: (a) such provision will be deemed amended to
         conform to applicable laws of such jurisdiction so as to be valid and
         enforceable, or, if it cannot be so amended without materially altering
         the intention of the parties, it will be stricken; (b) the validity,
         legality and enforceability of such provision will not in any way be
         affected or impaired thereby in any other jurisdiction; and (c) the
         remaining provisions of this Agreement will remain in full force and
         effect.

16.3     Survival. The covenants and agreements set forth in ARTICLES 7, 11 AND
         13 shall survive any termination or expiration of this Agreement and
         remain in full force and effect regardless of the cause of termination.

16.4     Entire Agreement. This Agreement, including the attached Exhibits,
         constitutes the entire agreement of the Parties with respect to the
         subject matter, and supersedes all prior or contemporaneous
         understandings or agreements, whether written or oral, between
         Connetics and APG with respect to such subject matter, including but
         not limited to the Original Agreement and Term Sheet dated April 15,
         2003. In particular, (a) in the event of a conflict between this
         Agreement and the terms and conditions of any purchase order or other
         form generated in performance of this Agreement, then the terms and
         conditions of this Agreement shall control except insofar as any such
         purchase order or confirmation establishes:

                  (i)      the quantity and form of any Product ordered;

                  (ii)     the shipment date;

                  (iii)    the shipment routes and destinations; or

                  (iv)     the carrier;

         and (b) in the event of conflict between this Agreement and the Quality
         Agreement (as it may be amended from time to time), the terms of this
         Agreement shall govern all aspects of the relationship between the
         Parties except that the Quality Agreement shall govern with respect to
         quality matters.

16.5     Waivers. No waiver of any term or condition of this Agreement shall be
         valid or binding on either Party unless agreed in writing by the Party
         to be charged. The failure of either Party to enforce at any time, or
         for any period of time, any provision of this Agreement, or the failure
         to require at any time performance by the other Party of any provision
         of this Agreement, shall in no way be construed to be a present or
         future waiver of such provisions or of the right of such Party
         thereafter to enforce that provision or other provisions of this
         Agreement.

                                                                         PAGE 26

<PAGE>

16.6     Amendment. Except as set forth in SECTION 2.1, no amendment or
         modification of this Agreement shall be valid or binding upon the
         Parties unless made in writing and signed by the duly authorized
         representatives of both Parties.

16.7     Construction. The Parties agree that they have been represented by
         counsel during the execution and negotiation of this Agreement.
         Accordingly the Parties waive the application of any law, regulation,
         holding or rule of construction that provides that ambiguities in an
         agreement or other document will be construed against the party
         drafting such agreement or document.

16.8     Counterparts. This Agreement may be executed in two or more
         counterparts, each of which shall be deemed an original and all of
         which together shall constitute one and the same agreement. This
         Agreement may be signed and delivered to the other Party by facsimile
         signature; such transmission will be deemed a valid signature.

IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed
by their respective duly authorized officers as of the Effective Date.

Connetics Corporation                           APG

By: /s/ Greg Vontz                              By:  /s/ Robert E. Theroux
   ___________________________________              ____________________________

Title: EVP & COO                                Title: President & COO
      ________________________________                 _________________________

                                                                         PAGE 27

<PAGE>

                                LIST OF EXHIBITS

EXHIBIT A                   PRODUCTS

EXHIBIT B                   PRICING

EXHIBIT C                   QUALITY AGREEMENT

EXHIBIT D                   EQUIPMENT LIST

                                                                        EXHIBITS

<PAGE>

                                    EXHIBIT A

                                    PRODUCTS
[*]

[*]  Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to
the omitted portions.
<PAGE>

                                    EXHIBIT B

                                     PRICING

[*]

[*]  Certain information on this page has been omitted and filed separately
with the commission. Confidential treatment has been requested with respect to
the omitted portions.
<PAGE>

                                    EXHIBIT C

                                QUALITY AGREEMENT

Quality and Technical Agreement between Connetics Corporation and APG, dated
January 8, 2002, as amended effective September 13, 2002, as it may be further
amended from time to time.

                                                                        Exhibits

<PAGE>

                                    EXHIBIT D

                                 EQUIPMENT LIST

[*]

[*]  Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to
the omitted portions.<PAGE>

                                                                    EXHIBIT 10.1

                       LIMITED LIABILITY COMPANY AGREEMENT

                                       of

                                    NEOJB LLC

                      a Delaware limited liability company

                         Effective as of April 17, 2002

<PAGE>

                                TABLE OF CONTENTS

<TABLE>
<S>                                                                                                                     <C>
ARTICLE 1 ORGANIZATIONAL MATTERS.................................................................................       1
         1.1      Formation of Limited Liability Company.........................................................       1
         1.2      Name...........................................................................................       1
         1.3      Principal Place of Business; Other Places of Business..........................................       1
         1.4      Business Purpose...............................................................................       1
         1.5      Certificate of Formation; Filings..............................................................       2
         1.6      Registered Office and Designated Agent for Service of Process..................................       2
         1.7      Term...........................................................................................       2
ARTICLE 2 DEFINITIONS............................................................................................       2
         2.1      "Acceptance Notice"............................................................................       2
         2.2      "Acceptance Period"............................................................................       2
         2.3      "Additional Members"...........................................................................       2
         2.4      "Adjusted Capital Account".....................................................................       2
         2.5      "Affiliate"....................................................................................       2
         2.6      "Agreement"....................................................................................       3
         2.7      "Assignee".....................................................................................       3
         2.8      "Board of Managers"............................................................................       3
         2.9      "Capital Account"..............................................................................       3
         2.10     "Capital Call".................................................................................       4
         2.11     "Capital Contributions"........................................................................       4
         2.12     "Cash Available for Distribution"..............................................................       4
         2.13     "Certificate"..................................................................................       4
         2.14     "Change of Control"............................................................................       4
         2.15     "Class A Members"..............................................................................       4
         2.16     "Code".........................................................................................       4
         2.17     "Company"......................................................................................       4
         2.18     "Company Assets"...............................................................................       5
         2.19     "Contribution Date"............................................................................       5
         2.20     "Covered Person"...............................................................................       5
         2.21     "Delaware LLC Act".............................................................................       5
         2.22     "Depreciation".................................................................................       5
         2.23     "Economic Interest"............................................................................       5
         2.24     "Effective Date"...............................................................................       5
         2.25     "Excess Capital Contribution"..................................................................       5
         2.26     "FDA"..........................................................................................       5
         2.27     "GAAP".........................................................................................       5
         2.28     "Gross Asset Value"............................................................................       5
         2.29     "Investment Interests".........................................................................       6
         2.30     "Investment Members"...........................................................................       6
         2.31     "JAMS".........................................................................................       6
         2.32     "JBCPL" and "JBSOL"............................................................................       6
         2.33     "Majority in Interest".........................................................................       7
         2.34     "Manager"......................................................................................       7
         2.35     "Members"......................................................................................       7
</TABLE>

                                       i

<PAGE>

<TABLE>
<S>                                                                                                                    <C>
         2.36     "Membership Interest" or "Interest"............................................................       7
         2.37     "Negotiation Period"...........................................................................       7
         2.38     "NeoTherapeutics"..............................................................................       7
         2.39     "Net Profits" or "Net Losses"..................................................................       7
         2.40     "Note".........................................................................................       8
         2.41     "Operating Cash Expenses"......................................................................       8
         2.42     "Percentage Interest"..........................................................................       8
         2.43     "Person".......................................................................................       8
         2.44     "Prime Rate"...................................................................................       8
         2.45     "Product"......................................................................................       8
         2.46     "Proportionate" and "Proportionately"..........................................................       8
         2.47     "Records"......................................................................................       8
         2.48     "Regulations"..................................................................................       8
         2.49     "Regulatory Allocations".......................................................................       8
         2.50     "Reserves".....................................................................................       8
         2.51     "Responsible Party"............................................................................       9
         2.52     "Securities Act"...............................................................................       9
         2.53     "Selling Member"...............................................................................       9
         2.54     "Substitute Member"............................................................................       9
         2.55     "Supply Agreement".............................................................................       9
         2.56     "Terminating Capital Transaction"..............................................................       9
         2.57     "Total Amount".................................................................................       9
         2.58     "Transfer".....................................................................................       9
         2.59     "Unreturned Capital"...........................................................................       9
ARTICLE 3 CAPITALIZATION.........................................................................................       9
         3.1      Initial Capitalization of Company..............................................................       9
         3.2      Additional Capital Contributions by Members....................................................      10
         3.3      Capital Accounts...............................................................................      11
         3.4      Member Capital.................................................................................      11
         3.5      Member Loans...................................................................................      12
         3.6      Liability of Members...........................................................................      12
         3.7      Allocation of Costs............................................................................      12
ARTICLE 4 DISTRIBUTIONS..........................................................................................      13
         4.1      Timing and Amount of Distributions.............................................................      13
         4.2      Order of Distributions.........................................................................      13
         4.3      Distributions in Kind..........................................................................      13
         4.4      Withholding....................................................................................      13
ARTICLE 5 ALLOCATIONS OF NET PROFITS AND NET LOSSES..............................................................      14
         5.1      Allocation of Net Profits and Losses...........................................................      14
         5.2      Additional Special Allocations.................................................................      14
         5.3      Other Provisions...............................................................................      15
ARTICLE 6 GOVERNANCE AND OPERATIONS..............................................................................      16
         6.1      Board of Managers..............................................................................      16
         6.2      Election of Managers...........................................................................      16
         6.3      Powers and Authority of Board of Managers......................................................      17
</TABLE>

                                       ii

<PAGE>

<TABLE>
<S>                                                                                                                    <C>
         6.4      Amendment of Certificate or Agreement..........................................................      17
         6.5      Meetings.......................................................................................      18
         6.6      Officers.......................................................................................      18
         6.7      Records and Reports............................................................................      20
         6.8      Meetings of Members............................................................................      21
         6.9      Power to Bind Company..........................................................................      21
         6.10     Standards of Conduct...........................................................................      21
         6.11     Outside Activities of Members..................................................................      22
ARTICLE 7 INTERESTS AND TRANSFERS OF INTERESTS...................................................................      22
         7.1      Transfers of Membership Interests..............................................................      22
         7.2      Sale or Transfer of a Member's Interest........................................................      23
         7.3      Rights of Assignees............................................................................      24
         7.4      Admissions, Withdrawals and Removals...........................................................      24
         7.5      No Payment Upon Withdrawal of Member...........................................................      24
         7.6      Admission of Assignees as Substitute Members...................................................      24
         7.7      Withdrawal of Members..........................................................................      25
ARTICLE 8 LIABILITY, EXCULPATION, AND INDEMNIFICATION............................................................      25
         8.1      Liability......................................................................................      25
         8.2      Exculpation....................................................................................      25
         8.3      Indemnification of Covered Persons.............................................................      26
         8.4      Expenses.......................................................................................      26
         8.5      Insurance......................................................................................      26
ARTICLE 9 DISSOLUTION, LIQUIDATION, AND TERMINATION OF THE COMPANY...............................................      26
         9.1      Limitations....................................................................................      26
         9.2      Exclusive Causes...............................................................................      26
         9.3      Effect of Dissolution..........................................................................      27
         9.4      No Capital Contribution Upon Dissolution.......................................................      27
         9.5      Liquidation....................................................................................      27
ARTICLE 10 MISCELLANEOUS.........................................................................................      28
         10.1     Amendments.....................................................................................      28
         10.2     Accounting and Fiscal Year.....................................................................      28
         10.3     Entire Agreement...............................................................................      28
         10.4     Further Assurances.............................................................................      28
         10.5     Notices........................................................................................      29
         10.6     Tax Matters....................................................................................      29
         10.7     Governing Law; Certain Waivers.................................................................      29
         10.8     Captions - Pronouns............................................................................      29
         10.9     Binding Effect.................................................................................      29
         10.10    Confidentiality................................................................................      30
         10.11    Member Representations.........................................................................      30
         10.12    Counterparts...................................................................................      30
         10.13    Attorney Fees..................................................................................      30
         10.14    Titles.........................................................................................      31
         10.15    Successors.....................................................................................      31
</TABLE>

                                      iii

<PAGE>

<TABLE>
<S>                                                                                                                    <C>
         10.16    Computation of Time Periods....................................................................      31
         10.17    Severability...................................................................................      31
         10.18    Signatory Authority............................................................................      31
         10.19    Arbitration....................................................................................      31
         10.20    Lockup in Event of Initial Public Offering.....................................................      32
         10.21    Interpretations................................................................................      32
</TABLE>

                                    EXHIBITS

Exhibit A         Members, Capital Contributions and Percentage Interests

                                       iv

<PAGE>

                       LIMITED LIABILITY COMPANY AGREEMENT

                                       OF

                                    NEOJB LLC

                  This LIMITED LIABILITY COMPANY AGREEMENT (the "AGREEMENT") of
NeoJB LLC (the "COMPANY"), by and among those Persons whose names are set forth
on Exhibit A hereto (as such may be amended from time to time) (collectively,
the "MEMBERS," with each being referred to, individually, as a "MEMBER"), is
made effective as of April 16, 2002 (the "EFFECTIVE DATE").

                                   ARTICLE 1
                             ORGANIZATIONAL MATTERS

                  1.1      FORMATION OF LIMITED LIABILITY COMPANY. The Members
formed the Company as a limited liability company under the Delaware Limited
Liability Company Act (as such may be amended from time to time, the "DELAWARE
LLC ACT") for the purposes of obtaining regulatory approval, distributing and
marketing in the United States products produced by JB Chemicals and
Pharmaceuticals, Ltd. of Mumbai, India, and upon the terms and conditions set
forth in this Agreement. The rights, powers, duties and liabilities of the
Members shall be as provided in the Delaware LLC Act, except as otherwise
expressly provided herein. In the event of any inconsistency between any terms
and conditions contained in the Agreement and any non-mandatory provisions of
the Delaware LLC Act, the Agreement shall govern.

                  1.2      NAME. The name of the Company shall be "NeoJB, LLC."
The Company may conduct business under one or more fictitious names as
determined by the Board of Managers.

                  1.3      PRINCIPAL PLACE OF BUSINESS; OTHER PLACES OF
BUSINESS. The principal place of business of the Company is 157 Technology
Drive, Irvine, California 92618, or such other place as determined by the Board
of Managers. The Company may maintain offices and places of business at such
other place or places within or outside the State of Delaware as determined by
the Board of Managers.

                  1.4      BUSINESS PURPOSE. The Company has been formed to
implement a joint venture between NeoTherapeutics, Inc. ("NEOTHERAPEUTICS") and
J.B. Chemicals & Pharmaceuticals, Ltd. ("JBCPL") and/or its wholly owned
subsidiary, JB Life Science Overseas Ltd. ("JBSOL") for the purposes of
obtaining regulatory approval in the United States for patented and/or
proprietary pharmaceuticals, intermediates, bulk chemicals, finished
pharmaceuticals and natural products of JBCPL (each, a "PRODUCT") and to engage
in the distribution and sale of the Products in the United States. It is
anticipated that the Company and JBCPL shall enter into one or more Supply
Agreement(s) (each, a "SUPPLY AGREEMENT") in a form reasonably acceptable to
both the Company and JBCPL, related to the supply of one or more Products by
JBCPL to the Company and providing for the grant or license by JBCPL to the
Company of all intellectual property rights necessary to enable the Company to
obtain regulatory

<PAGE>

approval of the subject Products in the United States. Notwithstanding the
foregoing, subject to the limitations set forth in this Agreement, the Company
may carry on any lawful business, purpose or activity, whether or not for
profit, with the exception of the business of the granting of policies of
insurance, or assuming insurance risks or banking as defined in Section 126 of
the Delaware General Corporation Law, and shall have the power to do and perform
all things determined by the Board of Managers to be necessary, desirable or
appropriate for, incident to or connected with or arising out of the business,
purposes or activities of the Company.

                  1.5      CERTIFICATE OF FORMATION; FILINGS. The Members have
caused to be executed and filed a Certificate of Formation (the "CERTIFICATE")
in the Office of the Delaware Secretary of State. The Board of Managers may
execute and file any duly authorized amendments to the Certificate from time to
time in a form prescribed by the Delaware LLC Act. The Board of Managers shall
also cause to be made, on behalf of the Company, such additional filings and
recordings as it shall deem necessary or advisable.

                  1.6      REGISTERED OFFICE AND DESIGNATED AGENT FOR SERVICE OF
PROCESS...The Company shall continuously maintain a registered office and a
designated and duly qualified agent for service of process for the Company in
the State of Delaware. The address of the registered office in Delaware and of
the registered agent for service of process as of the effective date of this
Agreement is The Delaware Limited Liability Company.

                  1.7      TERM. The Company commenced existence on the date
that the Certificate was first properly filed with the Office of the Delaware
Secretary of State, and shall continue perpetually until duly terminated.

                                    ARTICLE 2
                                   DEFINITIONS

         Capitalized words and phrases used and not otherwise defined elsewhere
in this Agreement shall have the following meanings:

                  2.1      "ACCEPTANCE NOTICE" is defined in Section 6.11.2.

                  2.2      "ACCEPTANCE PERIOD" is defined in Section 6.11.2.

                  2.3      "ADDITIONAL MEMBERS" means those Persons admitted as
Members pursuant to Section 3.1.2 or Section 3.2.1.

                  2.4      "ADJUSTED CAPITAL ACCOUNT" means, with respect to any
Member, the balance, if any, in such Member's Capital Account as of the end of
the relevant fiscal year, after adding to such Capital Account the amount that
such Member is deemed to be obligated to restore pursuant to Regulations
Sections 1.704-2(g)(1) and 1.704-2(i)(5), and subtracting from such Capital
Account such Member's share of the items described in Regulations Sections
1.704-1(b)(2)(ii)(d)(4), (5) and (6).

                  2.5      "AFFILIATE" means, with reference to a specified
Person: (a) a Person that, directly or indirectly, controls, is controlled by,
or is under common control with, the specified Person, or (b) any Person that is
an officer, director, general partner, manager or managing

                                       2

<PAGE>

member, or trustee of, or serves in a similar capacity with respect to, the
specified Person, or for which the specified Person is an officer, director,
general partner, manager or managing member, or trustee, or serves in a similar
capacity.

                  2.6      "AGREEMENT" is defined in the Preamble.

                  2.7      "ASSIGNEE" means any Person (a) to whom a Member (or
Assignee thereof) Transfers all or any part of its Interest and (b) which has
not been admitted as a Substitute Member pursuant to Section 7.5.

                  2.8      "BOARD OF MANAGERS" means those Persons elected as
members of the Board of Managers pursuant to this Agreement or any Person(s)
succeeding any of them in that capacity.

                  2.9      "CAPITAL ACCOUNT" means a Capital Account maintained
for each Member in accordance with the following provisions:

                           2.9.1    To each Member's Capital Account there shall
be added (a) such Member's Capital Contributions and (b) such Member's allocable
share of Net Profits and any items in the nature of income or gain that are
specially allocated to such Member pursuant to Article 5 hereof or other
provisions of this Agreement.

                           2.9.2    From each Member's Capital Account there
shall be subtracted (a) the amount of (i) cash distributed to such Member, and
(ii) the Gross Asset Value of any Company Assets distributed to such Member in
kind pursuant to any provision of this Agreement (net of liabilities encumbering
the distributed Company Assets that such Member is considered to assume or take
subject to under Section 752 of the Code), (b) such Member's allocable share of
Net Losses and any other items in the nature of expenses or losses that are
specially allocated to such Member pursuant to Article 5 hereof and (c)
liabilities of such Member assumed by the Company or which are secured by any
property contributed by such Member to the Company, calculated by reference to
Section 752 of the Code. With respect to distributions of Company Assets in
kind, if any, Capital Accounts shall first be adjusted to reflect the manner in
which the unrealized income, gain, loss and deduction inherent in such assets
(that has not been previously reflected in Capital Accounts) would be allocated,
pursuant to Article 5 hereof, to the Members if there were a taxable disposition
of such assets for fair market value (taking Section 7701(g) of the Code into
account) on the date of distribution.

                           2.9.3    The Board of Managers may cause an increase
or decrease in the Capital Accounts of the Members to reflect a revaluation of
Company Assets on the Company's books and records. Any such adjustments shall be
made in accordance with Regulations Section 1.704-1(b)(2)(iv)(g).

                           2.9.4    Additional adjustments shall be made to the
Members' Capital Accounts as required by Regulations Sections 1.704-1(b) and
1.704-2 or, as permitted but not required, in the discretion of the Board of
Managers. Adjustments to Capital Accounts in respect to Company income, gain,
loss, deduction and non-deductible expenditures (or any item thereof) shall be
made with reference to the federal tax treatment of such items (and, in the case
of book

                                       3

<PAGE>

items, with reference to federal tax treatment of the corresponding tax items)
at the Company level, without regard to any requisite or elective tax treatment
of such items at the Member level.

                           2.9.5    The foregoing provisions and the other
provisions of this Agreement relating to the maintenance of Capital Accounts are
intended to comply with Regulations Sections 1.704-1(b) and 1.704-2 and shall be
interpreted and applied in a manner consistent with such Regulations.

                  2.10     "CAPITAL CALL" is defined in Section 3.2.1(d).

                  2.11     "CAPITAL CONTRIBUTIONS" means, with respect to any
Member, the total amount of money and the fair market value of property (other
than money) contributed to the capital of the Company by such Member, whether
contributed as an initial Capital Contribution or as an additional Capital
Contribution.

                  2.12     "CASH AVAILABLE FOR DISTRIBUTION" means, with respect
to any fiscal year, all Company cash receipts, after deducting payments for
Operating Cash Expenses, payments required to be made in connection with any
loan to the Company or any other loan secured by a lien on any Company Assets,
capital expenditures and any other amounts set aside for the restoration,
increase or creation of Reserves.

                  2.13     "CERTIFICATE" is defined in Section 1.5.

                  2.14     "CHANGE OF CONTROL" means (a) an acquisition of all
or substantially all of the assets of the Company, (b) a sale of Membership
Interests (other than through newly issued Membership Interests or other equity)
or a merger, consolidation, reorganization or other combination or acquisition
whereby the existing Members of the Company and their Affiliates do not retain
at least a majority of the voting power of the membership interests of the
Company or the other equity of the surviving entity or (c) after an initial
public offering of membership interests (or shares of common stock or other
securities of a successor corporation or entity of the Company into which the
Company may reorganize in contemplation of an initial public offering), the
acquisition by one person (within the meaning of Section 13(d)(3) under the
Securities Exchange Act of 1934, as amended) other than the securityholders
existing immediately prior to the initial public offering of beneficial
ownership of at least 30% of the Company's fully-diluted membership interests
(or shares of common stock or other securities of a successor corporation or
entity of the Company into which the Company may reorganize in contemplation of
an initial public offering).

                  2.15     "CLASS A MEMBERS" means the Persons identified as
such on Exhibit A to this Agreement, as such may be amended from time to time.

                  2.16     "CODE" means the Internal Revenue Code of 1986, as
amended from time to time (or corresponding provisions of succeeding law).

                  2.17     "COMPANY" is defined in the Preamble.

                                       4

<PAGE>

                  2.18     "COMPANY ASSETS" means all direct and indirect
interests in real and personal property owned by the Company, including both
tangible and intangible property (including cash).

                  2.19     "CONTRIBUTION DATE" is defined in Section 3.2.1(d).

                  2.20     "COVERED PERSON" means each member of the Board of
Managers, any Member, an officer of the Company, a Person to whom the Board of
Managers duly delegates management responsibilities, an Affiliate of a Member,
or an employee or agent of the Company or of a Covered Person.

                  2.21     "DELAWARE LLC ACT" is defined in the Preamble.

                  2.22     "DEPRECIATION" means, for each fiscal year, an amount
equal to the federal income tax depreciation, amortization or other cost
recovery deduction allowable with respect to an asset for such year or other
period, except that (a) with respect to any asset the Gross Asset Value of which
differs from its adjusted tax basis for federal income tax purposes, which
difference is being eliminated by use of the "remedial method" pursuant to
Section 1.704-3(d) of the Regulations, Depreciation for such fiscal year shall
be the amount of book basis recovered for such fiscal year under the rules
prescribed by Section 1.704-3(d)(2) of the Regulations, and (b) with respect to
any other asset the Gross Asset Value of which differs from its adjusted basis
for federal income tax purposes at the beginning of such year, Depreciation
shall be an amount that bears the same ratio to such beginning Gross Asset Value
as the federal income tax depreciation, amortization or other cost recovery
deduction for such year or other period bears to such beginning adjusted tax
basis; provided, however, that if the federal income tax depreciation,
amortization or other cost recovery deduction for such year is zero,
Depreciation shall be determined with reference to such beginning Gross Asset
Value using any method selected by the Board of Managers.

                  2.23     "ECONOMIC INTEREST" means a Person's right to share
in the Net Profits, Net Losses, or similar items of, and to receive
distributions from, the Company, but does not include any other rights of a
Member, including, without limitation, the right to vote or to participate in
the management of the Company, or, except as specifically provided in this
Agreement or required under the Delaware LLC Act, any right to information
concerning the business and affairs of the Company.

                  2.24     "EFFECTIVE DATE" is defined in the Preamble.

                  2.25     "EXCESS CAPITAL CONTRIBUTION" is defined in Section
3.2.3.

                  2.26     "FDA"means the United States Food and Drug
Administration.

                  2.27     "GAAP" is defined in Section 3.5.1.

                  2.28     "GROSS ASSET VALUE" means, with respect to any asset,
the asset's adjusted basis for federal income tax purposes, except as follows:

                                       5

<PAGE>

                           2.28.1   The initial Gross Asset Value of any asset
contributed by a Member to the Company shall be the gross fair market value of
such asset, as provided herein or as determined by the Board of Managers.

                           2.28.2   The Gross Asset Values of all Company Assets
immediately prior to the occurrence of any event described in subsection (a),
subsection (b), subsection (c) or subsection (d) hereof shall be adjusted to
equal their respective gross fair market values, as determined by the Board of
Managers, as of the following times:

                                    (a)      the acquisition of an additional
         interest in the Company (other than in connection with the execution of
         this Agreement) by a new or existing Member in exchange for more than a
         nominal Capital Contribution;

                                    (b)      the distribution by the Company to
         a Member of more than a nominal amount of Company property as
         consideration for an interest in the Company;

                                    (c)      the liquidation of the Company
         within the meaning of Regulations Section 1.704-1(b)(2)(ii)(g); and

                                    (d)      at such other times as the Board of
         Managers may determine as necessary or advisable in order to comply
         with Regulations Sections 1.704-1(b) and 1.704-2.

                           2.28.3   The Gross Asset Value of any Company Asset
distributed to a Member shall be the gross fair market value of such asset on
the date of distribution, as determined by the Board of Managers.

                           2.28.4   The Gross Asset Values of Company Assets
shall be increased (or decreased) to reflect any adjustments to the adjusted
basis of such assets pursuant to Section 734(b) or Section 743(b) of the Code,
but only to the extent that such adjustments are taken into account in
determining Capital Accounts pursuant to Regulations Section
1.704-1(b)(2)(iv)(m).

                           2.28.5   If the Gross Asset Value of a Company asset
has been determined or adjusted pursuant to Section 2.27.1, Section 2.27.2 or
Section 2.27.4 above, such Gross Asset Value shall thereafter be adjusted by the
Depreciation taken into account with respect to such asset for purposes of
computing Net Profits and Net Losses.

                  2.29     "INVESTMENT INTERESTS" is defined in Section
3.2.1(c).

                  2.30     "INVESTMENT MEMBERS" means the Person(s), if any, who
are granted Investment Interests pursuant to Section 3.2.1(c) and who are
identified as Investment Members on Exhibit A to this Agreement, as such may be
amended from time to time.

                  2.31     "JAMS" is defined in Section 10.20.

                  2.32     "JBCPL" AND "JBSOL" are defined in Section 1.4.

                                       6

<PAGE>

                  2.33     "MAJORITY IN INTEREST" means Members entitled to vote
(or any specified subset thereof) holding, in the aggregate, a majority of the
Percentage Interests entitled to vote held by all Members entitled to vote (or
by such specified subset).

                  2.34     "MANAGER" is defined in Section 6.2.1.

                  2.35     "MEMBERS" means the Persons owning Membership
Interests, including any Additional Members and any Substitute Members, with
each Member being referred to, individually, as a "MEMBER."

                  2.36     "MEMBERSHIP INTEREST" or "INTEREST" means the entire
ownership interest of a Member in the Company at any particular time, including,
without limitation, the Member's Economic Interest, the right to vote and
otherwise participate in the Company's affairs, and the right to the benefits to
which a Member may be entitled as provided in this Agreement, together with the
obligations of such Member to comply with all of the terms and provisions of
this Agreement.

                  2.37     "NEGOTIATION PERIOD" is defined in Section 6.11.3.

                  2.38     "NEOTHERAPEUTICS" is defined in Section 1.4.

                  2.39     "NET PROFITS" or "NET LOSSES" means, for each fiscal
year or other period, an amount equal to the Company's taxable income or loss
for such year or period determined in accordance with Section 703(a) of the Code
(for this purpose, all items of income, gain, loss or deduction required to be
stated separately pursuant to Section 703(a)(1) of the Code shall be included in
taxable income or loss), with the following adjustments:

                           2.39.1   Any income of the Company that is exempt
from federal income tax and not otherwise taken into account in computing Net
Profits or Net Losses pursuant to this Section 2.38 shall be added to such
taxable income or loss.

                           2.39.2   Any expenditure of the Company described in
Section 705(a)(2)(B) of the Code or treated as a Section 705(a)(2)(B)
expenditure pursuant to Regulations Section 1.704-1(b)(2)(iv)(i), and not
otherwise taken into account in computing Net Profits or Net Losses pursuant to
this Section 2.38, shall be subtracted from such taxable income or loss.

                           2.39.3   Gain or loss resulting from any disposition
of each Company Asset where such gain or loss is recognized for federal income
tax purposes shall be computed by reference to the Gross Asset Value of the
Company Asset disposed of, notwithstanding that the adjusted tax basis of such
Company Asset differs from its Gross Asset Value.

                           2.39.4   To the extent an adjustment to the adjusted
tax basis of any asset included in the Company Assets pursuant to Section 734(b)
or Section 743(b) of the Code is required pursuant to Regulations Section
1.704-1(b)(2)(iv)(m)(4) to be taken into account in determining Capital Accounts
as a result of a distribution other than in liquidation of a Member's Membership
Interest, the amount of such adjustment shall be treated as an item of gain (if
the adjustment increases the basis of the asset) or loss (if the adjustment
decreases the basis of the

                                       7

<PAGE>

asset) from the disposition of the asset and shall be taken into account for the
purposes of computing Net Profits and Net Losses.

                           2.39.5   If the Gross Asset Value of any Company
Asset is adjusted in accordance with the terms of this Agreement, the amount of
such adjustment shall be taken into account in the taxable year of such
adjustment as gain or loss from the disposition of such asset for purposes of
computing Net Profits or Net Losses.

                           2.39.6   Notwithstanding any other provision of this
Section 2.38, any items that are specially allocated pursuant to Section 5.2
hereof shall not be taken into account in computing Net Profits or Net Losses.

                  2.40     "NOTE" is defined in Section 3.5.1.

                  2.41     "OPERATING CASH EXPENSES" means, with respect to any
fiscal period, the amount of cash disbursed in the ordinary course of business
during the period, for operating expenses of the Company, for capital
expenditures not paid from Capital Contributions, and for Reserves actually
funded. Operating Cash Expenses shall not include expenditures paid from
Reserves or other non-cash expenses such as depreciation or amortization.

                  2.42     "PERCENTAGE INTEREST" means, with respect to each
Member, the percentage set forth opposite such Member's name on Exhibit A,
attached hereto and, as it may be amended, modified or supplemented from time to
time, incorporated herein.

                  2.43     "PERSON" means and includes an individual, a
corporation, a partnership, a limited liability company or partnership, a trust,
an unincorporated organization, a government or any department or agency
thereof, or any other juridical entity.

                  2.44     "PRIME RATE" means the highest prime or reference
rate as quoted from time to time by Bank of America, N.A., which shall be a
variable rate. Interest rates set forth in this Agreement that are determined
with reference to the Prime Rate shall similarly be variable rates and shall
change immediately effective upon a change in the Prime Rate.

                  2.45     "PRODUCT" is defined in Section 1.4.

                  2.46     "PROPORTIONATE" and "PROPORTIONATELY" means, when
used with respect to the Members (or a group of them), the proportion that each
such Member's Percentage Interest bears to the total outstanding Percentage
Interests of all Members to whom reference is made.

                  2.47     "RECORDS" is defined in Section 6.7.3.

                  2.48     "REGULATIONS" means Treasury Regulations promulgated
under the Code and in effect, as such Regulations may be amended and succeeded
from time to time.

                  2.49     "REGULATORY ALLOCATIONS" is defined in Section 5.2.9.

                  2.50     "RESERVES" means funds set aside or amounts allocated
to reserves that shall be maintained in amounts determined by the Board of
Managers for working capital, to pay

                                       8

<PAGE>

taxes, insurance, debt service and other costs or expenses and liabilities
(actual and contingent) incident to the conduct of business by the Company or
the liquidation of its assets and termination of its existence.

                  2.51     "RESPONSIBLE PARTY" is defined in Section 6.10.1.

                  2.52     "SECURITIES ACT" is defined in Section 3.2.2.

                  2.53     "SELLING MEMBER" is defined in Section 7.2.

                  2.54     "SUBSTITUTE MEMBER" means any Person (a) to whom a
Member (or Assignee thereof) Transfers all or any part of its Interest, and (b)
which has been admitted to the Company as a Substitute Member pursuant to
Section 7.5.

                  2.55     "SUPPLY AGREEMENT" is defined in Section 1.4.

                  2.56     "TERMINATING CAPITAL TRANSACTION" means any sale or
other disposition of all or substantially all of the assets of the Company or a
related series of transactions that, taken together, result in the sale or other
disposition of all or substantially all of the assets of the Company.

                  2.57     "TOTAL AMOUNT" is defined in Section 3.2.1(d).

                  2.58     "TRANSFER" means, with respect to any Interest, a
sale, conveyance, exchange, assignment, pledge, encumbrance, gift, bequest,
hypothecation or other transfer or disposition by any other means, whether for
value or not and whether voluntary or involuntary (including, without
limitation, by operation of law), or an agreement to do any of the foregoing.
Used as a verb, the term shall mean effecting any of the foregoing.

                  2.59     "UNRETURNED CAPITAL" means, with respect to each
Member, the cumulative Capital Contributions by such Member less (a) the amount
of any liabilities to which any assets contributed by the Member are subject at
the time of contribution or which are otherwise assumed by the Company in
connection with such contribution(s) and (b) the distributions to such Member
with respect to such Member's Unreturned Capital.

                                   ARTICLE 3
                                 CAPITALIZATION

                  3.1      INITIAL CAPITALIZATION OF COMPANY. The names,
addresses, initial Capital Contributions and Percentage Interests of the Members
are set forth on Exhibit A. All Members acknowledge and agree that the initial
Capital Contributions set forth in Exhibit A represent the amount of cash and
the fair market value of property other than cash initially contributed by the
Members.

                                       9

<PAGE>

                  3.2      ADDITIONAL CAPITAL CONTRIBUTIONS BY MEMBERS.

                           3.2.1    If the Board of Managers determines that the
Company requires or would benefit from additional funds, the Board of Managers,
on behalf of the Company, may, but shall not be obligated to, do any of the
following:

                                    (a)      THIRD PARTY DEBT FINANCING. Obtain
         the funds via third-party debt financing from one or more sources and
         on terms and conditions acceptable to the Board of Managers (which may
         include, for example, (i) the granting of a lien or liens on certain or
         all of the Company Assets to secure repayment or (ii) the granting of a
         Membership Interest or Economic Interest and/or the right to
         subsequently convert all or a portion of the loan funds provided into a
         Membership Interest or Economic Interest).

                                    (b)      VOLUNTARY MEMBER LOANS. Obtain the
         funds via voluntary Member loans to the Company, of all or a portion of
         the total funds required. Such loans shall be considered permitted
         Member loans. Unless otherwise determined by the Board of Managers at
         the time voluntary Member loans are obtained, all voluntary Member
         loans under this Section 3.2.1(b) shall be payable upon demand, shall
         bear interest quarterly in arrears at the Prime Rate in effect on the
         first day of the applicable quarter and shall not be convertible into
         additional Membership Interests of the Company. If multiple Members are
         interested in making loans to the Company, and the aggregate amount
         that such Members wish to loan exceeds the total amount of required
         funds as determined by the Board of Managers, each interested Member
         may loan his or its Proportionate share of the required funds. If any
         Member does not wish to loan his or its entire Proportionate share of
         the required funds, such share may be lent by the other interested
         Members on a Proportionate basis. This process shall be repeated until
         all required funds have been received, but in no event longer than
         fifteen (15) days after the Board of Managers has sent out a written
         notice to all Members soliciting loans pursuant to this Section
         3.2.1(b).

                                    (c)      INVESTMENT INTERESTS. Obtain the
         funds via one or more issuances of one or more separate class of
         Interests ("INVESTMENT INTERESTS"), the terms and conditions of each
         issuance of which, and the rights, preferences, privileges and
         obligations associated with the ownership of which, are determined by
         the Board of Managers and set forth in a written instrument delivered
         to all Members. Notwithstanding the provisions of Section 6.4, the
         Board of Managers may amend this Agreement to create and give
         effect to the rights, preferences, privileges and obligations any class
         of Investment Interests issued in accordance with this Section 3.2.1(c)
         without the consent of the Members. Prior to issuing any Investment
         Interests to outside persons in exchange for funds, such
         interests shall first be offered to existing Members on a Proportionate
         basis, and if an existing Member does not purchase his entire
         Proportionate share of the Investment Interests being offered to him,
         such share may be purchased by the other Members on a Proportionate
         basis. This process shall be repeated until all of the Investment
         Interests have been purchased by the existing Members or until no
         existing Member has any further interest in purchasing the Investment
         Interests, but in no event longer than fifteen (15) days after the
         Board of Managers has sent out a written notice to all Members
         soliciting the purchase of the Investment Interests and setting forth

                                       10

<PAGE>

         the material terms and conditions pertinent thereto. If existing
         Members do not purchase all of the Investment Interests, the
         unpurchased Investment Interests shall then be offered to outside
         investors (including any interested Affiliates of one or more of the
         Members) on the same terms and conditions offered to the Members. Upon
         issuance of one or more Investment Interests pursuant hereto, the
         Percentage Interests of all other Members shall be diluted on a
         Proportionate basis, and the Board of Managers shall revise Exhibit A
         appropriately and distribute the revised version to all of the Members.

                                    (d)      VOLUNTARY MEMBER CAPITAL
         CONTRIBUTIONS. Obtain the funds via voluntary Member Capital
         Contributions, which shall be solicited via written notice from the
         Board of Managers (a "CAPITAL CALL") to all Members specifying the
         total amount of capital to be obtained via Capital Contributions
         pursuant to the Capital Call ("TOTAL AMOUNT"), the use(s) therefor,
         each Member's Proportionate share of the Total Amount and the date by
         which Capital Contributions in response to the Capital Call are to be
         made (the "CONTRIBUTION DATE"). Each Member shall be entitled to elect
         to make a Capital Contribution in response to the Capital Call, equal
         to his or its Proportionate share of the Total Amount specified
         therein, by making a Capital Contribution of all or any portion of such
         amount by the Contribution Date. If any Member does not contribute his
         or its entire Proportionate share of the Total Amount by the
         Contribution Date, no Member may contribute a greater relative portion
         of its Proportionate share than that contributed by the Member
         contributing the smallest relative portion of its Prportionate share,
         so that no Member shall have contributed more than such Member's
         Proportionate share of the total amount contributed under this Section
         3.2.1(d). Any additional contributions made by any Member shall be
         deemed to be Voluntary Member loans made under Section 3.2.1(b).

                                    (e)      However, no person may loan funds
         pursuant to (b) above, make an investment (or additional investment) in
         the Company pursuant to (c) above or make a contribution pursuant to
         (d) above unless such person is, at the time his money is to be lent,
         invested or contributed, an "accredited investor" as that term is
         defined in Regulation D promulgated under the Securities Act of 1933,
         as amended (the "SECURITIES ACT").

                           3.2.2    Except as provided in Section 3.2.1, no
Member shall be permitted or required to make any additional Capital
Contributions to the Company.

                           3.2.3    Except as explicitly provided in this
Agreement to the contrary, no Member nor any other Person or Persons shall be
obligated to guarantee any Company borrowings.

                  3.3      CAPITAL ACCOUNTS. A Capital Account shall be
established and maintained for each Member.

                  3.4      MEMBER CAPITAL. Except as otherwise provided in this
Agreement or with the prior written consent of the Board of Managers: (a) no
Member shall demand or be entitled to receive a return of or interest on its
Capital Contributions or Capital Account; (b) no Member shall withdraw any
portion of its Capital Contributions or receive any distributions from

                                       11

<PAGE>

the Company as a return of capital on account of such Capital Contributions; and
(c) the Company shall not redeem or repurchase the Interest of any Member.

                  3.5      MEMBER LOANS. Except as otherwise provided in this
Agreement, or as otherwise determined by the Board of Managers, no Member shall
be required or permitted to make any loans or otherwise lend any funds to the
Company. Except as otherwise permitted or provided in this Agreement, no loans
made by any Member to the Company shall have any effect on such Member's
Percentage Interest or Capital Account. Each Member loan shall represent a debt
of the Company payable or collectible solely from the assets of the Company in
accordance with the terms and conditions upon which such loan was made. All
permitted Member loans shall be repaid in accordance with any documents and
instruments evidencing such loans or, absent any such documents or instruments,
shall be repaid prior to making any distributions to the Members.

                  3.6      LIABILITY OF MEMBERS. Except as otherwise required by
any non-waivable provision of the Delaware LLC Act or other applicable law: (a)
no Member shall be personally liable for any debt, liability or other obligation
of the Company; and (b) no Member shall have any liability to any Person in
excess of (i) the amount of its Capital Contributions and (ii) without
duplication, its share of any assets and undistributed profits of the Company.

                  3.7      ALLOCATION OF COSTS.

                           3.7.1    Until the earliest time at which each
Product then subject to a Supply Agreement has been approved by the FDA to be
marketed and sold in the United States, subject to the terms of any Supply
Agreement, NeoTherapeutics shall bear all direct and indirect costs incurred by
or on behalf of the Company in the United States in connection with obtaining
such regulatory approval in the United States, including without limitation all
costs related to clinical and pre-clinical testing conducted in the United
States, required product testing, and costs associated with the preparation and
filing of required Abbreviated New Drug Applications and New Drug Applications.
NeoTherapeutics may bear such costs by advancing funds to the Company, paying
costs directly on the Company's behalf or providing required services at no cost
to the Company, at NeoTherapeutics' sole discretion.

                           3.7.2    Until the earliest time at which each
Product then subject to a Supply Agreement has been approved by the FDA to be
marketed and sold in the United States, subject to the terms of any Supply
Agreement, JBCPL shall bear all direct and indirect costs incurred by or on
behalf of the Company outside of the United States in connection with obtaining
such regulatory approval in the United States, including without limitation all
costs related to manufacture of Products for the purpose of conducting clinical
and pre-clinical testing in India. JBCPL and/or JBSOL may bear such costs by
advancing funds to the Company, paying costs directly on the Company's behalf or
providing required goods or services at no cost to the Company, at JBCPL's
and/or JBSOL's sole discretion.

                           3.7.3    Until the earliest time at which each
Product then subject to a Supply Agreement has been approved by the FDA to be
marketed and sold in the

                                       12

<PAGE>

United States, subject to the terms of any Supply Agreement, the Company shall
bear all direct and indirect costs incurred by or on behalf of the Company for
matters not directly related to obtaining such approvals, including without
limitation, costs associated with general administration, Federal and state
taxes, required business licenses, marketing and marketing research,
distribution and legal, accounting and other professional fees. In addition, the
Company shall bear all direct and indirect costs and expenses associated with
ongoing required submissions to and approvals from various state and federal
regulatory agencies. From and after such time, subject to the terms of any
Supply Agreement, the Company shall bear all costs incurred by or on behalf of
the Company.

                                   ARTICLE 4
                                  DISTRIBUTIONS

                  4.1      TIMING AND AMOUNT OF DISTRIBUTIONS. Except as
otherwise provided in Article 9 hereof, all Cash Available for Distribution and
net proceeds from any Terminating Capital Transaction shall be distributed to
the Members at such times and in such amounts as determined by the Board of
Managers.

                  4.2      ORDER OF DISTRIBUTIONS. Any Cash Available for
Distribution shall be distributed as follows:

                           4.2.1    first, to the Members in proportion to and
to the extent of their respective amounts of Unreturned Capital;

                           4.2.2    then, to the Members with positive Adjusted
Capital Accounts, in proportion to and to the extent thereof; and

                           4.2.3    thereafter, to the Members in proportion to
their respective Percentage Interests.

                  4.3      DISTRIBUTIONS IN KIND. No Member shall have a right
to receive property other than cash as provided in this Agreement. The Board of
Managers may determine to make a distribution in kind of Company Assets to the
Members, and such Company Assets shall be distributed in such a fashion as to
ensure that the fair market value thereof is distributed and allocated in
accordance with this Article 4 and Articles 5 and 9 hereof.

                  4.4      WITHHOLDING. The Company may withhold distributions
or portions thereof if it is required to do so by any applicable rule,
regulation or law, and each Member hereby authorizes the Company to withhold
from or pay on behalf of or with respect to such Member any amount of federal,
state, local or foreign taxes that the Board of Managers determines that the
Company is required to withhold or pay with respect to any amount distributable
or allocable to such Member pursuant to this Agreement. Any amounts so paid or
withheld with respect to a Member pursuant to this Section 4.4 shall be treated
as having been distributed to such Member and shall reduce any amounts otherwise
distributable to such Member (either currently or in the future) pursuant to
Section 4.2 or Article 9.

                                       13

<PAGE>

                                   ARTICLE 5
                    ALLOCATIONS OF NET PROFITS AND NET LOSSES

                  5.1      ALLOCATION OF NET PROFITS AND LOSSES. Subject to
Sections 5.2 and 5.3 hereof, Net Profits, Net Losses and any other items of
income, gain, loss and deduction for any fiscal year shall be allocated, for
purposes of adjusting the Capital Accounts of the Members, as provided in this
Section 5.1:

                           5.1.1    The Net Losses of the Company shall be
allocated as follows:

                                    (a)      first, to the Members with positive
         Adjusted Capital Account Balances, in proportion to and to the extent
         thereof;

                                    (b)      thereafter, to the Members in
         proportion to their Percentage Interests.

                           5.1.2    The Net Profits shall be allocated as
follows:

                                    (a)      first, to the Members in proportion
         to and to the extent of the Net Losses allocated to them pursuant to
         Section 5.1.1(b);

                                    (b)      second, to the Members in the
         proportion and to the extent of the Net Losses allocated to them
         pursuant to Section 5.1.1(a);

                                    (c)      thereafter, to the Members in
         proportion to their respective Percentage Interests.

                  5.2      ADDITIONAL SPECIAL ALLOCATIONS. Notwithstanding the
foregoing provisions of this Article 5:

                           5.2.1    Tax items with respect to assets that are
contributed to the Company with a Gross Asset Value that varies from its basis
in the hands of the contributing Member immediately preceding the date of
contribution shall be allocated among the Members for income tax purposes
pursuant to Regulations promulgated under Section 704(c) of the Code so as to
take into account such variation. The Company shall account for such variation
under any method approved under Section 704(c) of the Code and the applicable
Regulations selected by the Board of Managers. If the Gross Asset Value of any
Company Asset is adjusted pursuant to Section 2.27.2 hereof, subsequent
allocations of income, gain, loss and deduction with respect to such asset shall
take account of any variation between the adjusted basis of such asset for
federal income tax purposes and its Gross Asset Value in the same manner as
under Section 704(c) of the Code and the Regulations promulgated thereunder.
Allocations pursuant to this Section 5.2.1 are solely for purposes of federal,
state and local taxes and shall not affect, or in any way be taken into account
in computing, any Member's Capital Account or share of Net Profits, Net Losses
and any other items or distributions pursuant to any provision of this
Agreement.

                           5.2.2    If any Member unexpectedly receives an
adjustment, allocation or distribution of the type contemplated by Regulations
Section 1.704-1(b)(2)(ii)(d)(4), (5) or (6)

                                       14

<PAGE>

that causes or increases a deficit Adjusted Capital Account, items of income and
gain shall be allocated to all such Members (in proportion to the amounts of
their respective deficit Adjusted Capital Accounts) in an amount and manner
sufficient to eliminate the deficit balances in such Members' Adjusted Capital
Accounts as quickly as possible as of the end of the Company's taxable year to
which such adjustment, allocation or distribution relates. It is intended that
this Section 5.2.6 qualify and be construed as a "qualified income offset"
within the meaning of Regulations Section 1.704-1(b)(2)(ii)(d).

                           5.2.3    To the extent that an adjustment to the
adjusted tax basis of any Company Asset pursuant to Section 734(b) or Section
743(b) of the Code is required, pursuant to Regulations Section
1.704-1(b)(2)(iv)(m)(2) or Regulations Section 1.704-1(b)(2)(iv)(m)(4), to be
taken into account in determining Capital Accounts as the result of a
distribution to a Member in complete liquidation of such Member's Membership
Interest in the Company, the amount of such adjustment to the Capital Accounts
shall be treated as an item of gain (if the adjustment increases the basis of
the asset) or loss (if the adjustment decreases such basis), and such gain or
loss shall be specially allocated to the Members in accordance with their
interests in the Company in the event that Regulations Section
1.704-1(b)(2)(iv)(m)(2) applies, or to the Members to whom such distribution was
made in the event that Regulations Section 1.704-1(b)(2)(iv)(m)(4) applies.

                           5.2.4    The allocations set forth in Sections 5.2.2
and 5.2.3 hereof (the "REGULATORY ALLOCATIONS") are intended to comply with
certain requirements of Regulations Sections 1.704-1(b) and 1.704-2(i). The
Regulatory Allocations may not be consistent with the manner in which the
Members intend to distribute the cash of the Company or allocate Company income
or loss. Accordingly, the Board of Managers is hereby authorized to cause the
allocation of Net Profits, Net Losses and other items of income, gain, loss and
deductions to the Members so as to prevent the Regulatory Allocations from
distorting the manner in which Company distributions will be divided among the
Members. In general, the Members anticipate that this will be accomplished by
specially allocating other Net Profits, Net Losses and other items of income,
gain, loss and deduction to the Members so that, to the extent possible, the net
amount of such allocations of other Net Profits, Net Losses and other items and
the Regulatory Allocations to the Members shall be equal to the net amount that
would have been allocated among the Members if the Regulatory Allocations had
not occurred.

                           5.2.5    For purposes of determining the Net Profits,
Net Losses and any other items of income, gain, loss and deduction allocable to
any period, Net Profits, Net Losses and any such other items shall be determined
on a daily, monthly or other basis, as determined by the Board of Managers using
any permissible method under Section 706 of the Code and the Regulations
thereunder.

                  5.3      OTHER PROVISIONS.

                           5.3.1    For any fiscal year during which any part of
a Membership Interest or Economic Interest is transferred between the Members or
to another Person, the portion of the Net Profits, Net Losses and other items of
income, gain, loss, deduction and credit that are allocable with respect to such
part of a Membership Interest or Economic Interest shall be

                                       15

<PAGE>

apportioned between the transferor and the transferee based on an interim
closing of the Company's books, except as otherwise mandated by the Code and the
applicable Regulations.

                           5.3.2    Except as provided in Section 5.2.1 hereof,
for income tax purposes under the Code and the Regulations each Company item of
income, gain, loss and deduction shall be allocated among the Members as its
correlative item of "book" income, gain, loss or deduction is allocated pursuant
to this Article 5.

                           5.3.3    In the event that the Code or any
Regulations require allocations of items of income, gain, loss, deduction or
credit different from those set forth in this Article 5, the Board of Managers
is hereby authorized to make new or different allocations in reliance on the
Code and such Regulations.

                                   ARTICLE 6
                            GOVERNANCE AND OPERATIONS

                  6.1      BOARD OF MANAGERS. Except for situations in which the
approval of the Members is required by statute or this Agreement, the Company
shall be managed and controlled by the Board of Managers. The Board of Managers
shall set the consideration, if any, to be paid to each member of the Board of
Managers for his or her services as a Manager, provided that any such
consideration shall be limited to ordinary and reasonable compensation.

                  6.2      ELECTION OF MANAGERS.

                           6.2.1    NUMBER, TERM AND QUALIFICATIONS. The Board
of Managers shall consist of five (5) Persons (each such Person, a "MANAGER").
NeoTherapeutics shall have the right to designate four (4) Managers and JBSOL
shall have the right to designate one (1) Manager. Unless a Manager resigns or
is removed, each Manager shall hold office until a successor shall have been
elected and qualified. The Managers initially designated by NeoTherapeutics
shall be Alvin J. Glasky, Ph.D. (Chairman), Rajesh Shrotriya, M.D., Ashok Gore,
Ph.D. and Samuel Gulko, and the Manager initially designated by JBSOL shall be
Dr. Satya Agarwala. A Manager need not be a Member, an individual, a resident of
the State of Delaware, or a citizen of the United States.

                           6.2.2    RESIGNATION. Any Manager may resign at any
time by giving written notice to the other Managers without prejudice to the
rights, if any, of the Company under any contract to which the Manager is a
party. The resignation of a Manager shall take effect upon receipt of that
notice or at such later time as shall be specified in the notice. Unless
otherwise specified in the notice, the acceptance of the resignation shall not
be necessary to make it effective. The resignation of a Manager who is also a
Member shall not affect the Manager's rights as a Member and shall not
constitute a withdrawal of a Member.

                           6.2.3    REMOVAL. Any Manager may be removed at any
time, with or without cause, by the Member that designated such Manager. Any
removal shall be without prejudice to the rights, if any, of the Manager under
any employment contract and, if the Manager is also a Member, shall not affect
the Manager's rights as a Member or constitute a withdrawal of a Member.

                                       16

<PAGE>

                           6.2.4    VACANCIES. Any vacancy occurring for any
reason in the number of Managers may be filled as designated by the Member that
designated the Manager whose resignation, removal or death created the vacancy.

                  6.3      POWERS AND AUTHORITY OF BOARD OF MANAGERS.

                           6.3.1    The powers and authority of the Board of
Managers shall be substantially the same as the powers and authority of the
board of directors of a Delaware corporation. The business of the Company shall
be managed by and under the direction of the Board of Managers, which may do all
lawful acts and things not by statute or by the Certificate or by this Agreement
required to be done by the Members. Unless otherwise provided in this Agreement,
the vote of the majority of the Managers shall be the act of the Board of
Managers.

                           6.3.2    Notwithstanding anything to the contrary
contained in this Agreement, none of the following actions shall be effected by
the Company or the Board of Managers without the written consent of
NeoTherapeutics and JBSOL:

                                    (a)      Materially change the Company's
         business as defined in Section 1.4;

                                    (b)      Sell, transfer or otherwise dispose
         of all or substantially all of the Company's assets;

                                    (c)      Enter into any merger, joint
         venture, partnership or other similar agreement; or

                                    (d)      Make a general assignment for the
         benefit of creditors, file a voluntary petition under the federal
         bankruptcy law, file a petition seeking an reorganization, arrangement,
         composition, readjustment, liquidation, dissolution or similar relief
         under any statute, law or regulation or seek, consent to or acquiesce
         in the appointment of a trustee, receiver or liquidator of the Company
         or all or any substantial part of its assets.

                  6.4      AMENDMENT OF CERTIFICATE OR AGREEMENT. This Agreement
may be amended from time to time with the approval of a majority of the Board of
Managers and approval by a Majority in Interest (except for those amendments
which expressly require something greater or less than a vote of a Majority in
Interest). Notwithstanding the foregoing, (a) any amendment which would
materially alter any individual Member's rights, as distinct from any Class's
rights, may only be made if the consent of the Member adversely affected thereby
is obtained prior to the effectiveness thereof and (b) any amendment which would
materially alter any individual Class's rights, as distinct from the rights of
the other Members, may only be made if the consent of a Majority in Interest of
the Class that is adversely affected thereby is obtained prior to the
effectiveness thereof. The Board of Managers shall amend the Certificate or this
Agreement as necessary to reflect any changes as a result of any action taken by
the Members.

                                       17

<PAGE>

                  6.5      MEETINGS. The Board of Managers will meet at least
quarterly. Regular meetings shall be scheduled on at least ten (10) days notice
and shall be held at reasonable times and places. Attendance at meetings may be
in person or by telephone or videoconference, provided that all Managers
participating in the meeting may hear each other. Unless otherwise provided in
this Agreement, any action required or permitted to be taken at a meeting of the
Managers may be taken without a meeting, without prior notice and without a
vote, if a consent in writing, setting forth the action to be so taken, shall be
signed by a majority of the Managers, which consents may be delivered to the
Company by electronic transmission, including transmission by facsimile or
electronic mail. Prompt notice of the taking of any such action without a
meeting by less than unanimous consent shall be given to those Managers that
have not consented in writing.

                  6.6      OFFICERS.

                           6.6.1    APPOINTMENT OF OFFICERS. The officers of the
Company shall be appointed by the Board of Managers and shall include a
President, a Treasurer (or Chief Financial Officer) and a Secretary. The Board
of Managers may appoint a Chairman, a Vice Chairman and/or one or more Vice
Presidents, Assistant Secretaries and Assistant Treasurers. Any number of
offices may be held by the same person. Any member of the Board of Managers may
hold any of the offices.

                           6.6.2    COMPENSATION OF OFFICERS. The compensation
of all officers and agents of the Company shall be fixed by the Board of
Managers and shall be limited to amounts that are ordinary and reasonable for
the services performed.

                           6.6.3    TERM OF OFFICE. The officers of the Company
shall hold office until their successors are chosen and qualified. Any officer
may be removed at any time by a majority of the Board of Managers. Any vacancy
occurring in any office of the Company shall be filled by the Board of Managers.

                           6.6.4    DUTIES OF SPECIFIC OFFICERS.

                                    (a)      DUTIES OF CHAIRMAN. The Chairman,
         if any, shall preside at all meetings of the Members at which the
         Chairman is present. The Chairman shall have and may exercise powers
         assigned from time to time to the Chairman by the Board of Managers and
         as are otherwise customarily associated with such office pursuant to
         the Delaware General Corporation Law.

                                    (b)      DUTIES OF VICE-CHAIRMAN. In the
         absence of the Chairman, the Vice Chairman, if any, shall preside at
         all meetings of the Members at which the Vice Chairman is present. The
         Vice Chairman shall have and may exercise powers assigned from time to
         time to the Vice Chairman by the Board of Managers and as are otherwise
         customarily associated with such office pursuant to the Delaware
         General Corporation Law.

                                    (c)      DUTIES OF PRESIDENT. The President
         shall be the chief executive officer of the Company, and in the absence
         of the Chairman and Vice Chairman shall preside at all meetings of the
         Members. The President shall have general

                                       18

<PAGE>

         and active management of the day-to-day business and affairs of the
         Company and shall see that all orders and resolutions of the Board of
         Managers are carried into effect. The President shall execute all
         contracts except where required or permitted by law to be otherwise
         signed and executed and except where the signing and execution has been
         expressly delegated by the Board of Managers to some other officer or
         agent of the Company.

                                    (d)      DUTIES OF VICE-PRESIDENT(S). In the
         absence of the President, the Vice President, if any (or, if there is
         more than one (1) Vice President, the Vice Presidents in the order
         designated by the Board of Managers, or in the absence of any
         designation, then in the order of their election) shall perform the
         duties of the President, and when so acting, shall have all the powers
         of and be subject to all the restrictions upon the President. Each Vice
         President shall perform other duties and have other powers as
         prescribed by the President or the Board of Managers or as are
         otherwise customarily associated with such office pursuant to the
         Delaware General Corporation Law.

                                    (e)      DUTIES OF SECRETARY. The Secretary
         shall attend all meetings of the Members and, if requested by the Board
         of Managers, shall record the proceedings of any such meeting of the
         Members and keep such written records in a book to be kept for that
         purpose. The Secretary shall give, or cause to be given, notice of all
         meetings of the Members and shall perform other duties and have other
         powers as prescribed by the Board of Managers or the President or as
         are otherwise customarily associated with such office pursuant to the
         Delaware General Corporation Law.

                                    (f)      DUTIES OF ASSISTANT SECRETARY(IES).
         The Assistant Secretary, if any (or, if there is more than one (1)
         Assistant Secretary, the Assistant Secretaries in the order designated
         by the Board of Managers, or in the absence of any designation, then in
         the order of their election) shall, in the absence of the Secretary or
         in the event of the Secretary's inability or refusal to act, perform
         the duties and exercise the powers of the Secretary and shall perform
         other duties and have other powers as prescribed by the Board of
         Managers, the President or the Secretary or as are otherwise
         customarily associated with such office pursuant to the Delaware
         General Corporation Law.

                                    (g)      DUTIES OF TREASURER (OR CHIEF
         FINANCIAL OFFICER). The Treasurer, or the Chief Financial Officer (both
         of which shall be referred to herein as the Treasurer), shall have the
         custody of the corporate funds and securities and shall keep full and
         accurate accounts of receipts and disbursements in books belonging to
         the Company and shall deposit all money and other valuables in the name
         and to the credit of the Company in depositories designated by the
         Board of Managers. The Treasurer shall disburse the funds of the
         Company ordered by the Board of Managers, taking proper vouchers for
         disbursements, and shall render to the President and the Board of
         Managers, at regular meetings, or when the Board of Managers so
         requires, an account of all transactions as Treasurer and of the
         financial condition of the Company.

                                       19

<PAGE>

                                    (h)      DUTIES OF ASSISTANT TREASURER(S).
         The Assistant Treasurer, if any (or, if there is more than one (1)
         Assistant Treasurer, the Assistant Treasurers in the order designated
         by the Board of Managers, or in the absence of any designation, then in
         the order of their election) shall, in the absence of the Treasurer or
         in the event of the Treasurer's refusal or inability to act, perform
         the duties and exercise the powers of the Treasurer and shall perform
         other duties and have other powers as prescribed by the Board of
         Managers, the President or the Treasurer or as are otherwise
         customarily associated with such office pursuant to the Delaware
         General Corporation Law.

                  6.7      RECORDS AND REPORTS.

                           6.7.1    The Board of Managers shall cause to be
kept, at the principal place of business of the Company, full and proper
ledgers, other books of account, and records of all receipts and disbursements,
other financial activities, and the internal affairs of the Company for at least
the current and past four (4) fiscal years, prepared, to the extent applicable,
in accordance with GAAP consistently applied.

                           6.7.2    As to each of the first three fiscal
quarters of the Company and each fiscal year of the Company, the Company shall
send to each Member a copy of (a) the balance sheet of the Company as of the end
of the fiscal quarter or year, (b) an income statement of the Company for such
quarter or year, and (c) a statement showing the amounts distributed by the
Company to Members in respect of such quarter or year. Such financial statements
shall be delivered no later than forty-five (45) days following the end of the
fiscal quarter to which the statements apply, except that the financial
statements relating to the end of the fiscal year shall be delivered no later
than ninety (90) days following the end of such fiscal year such financial
statements to be prepared, to the extent applicable, in accordance with GAAP
consistently applied.

                           6.7.3    The Board of Managers shall cause to be sent
to each Member of the Company, within ninety (90) days following the end of each
fiscal year of the Company or as soon thereafter as is reasonably practicable, a
report that shall include all necessary information required by each of the
Members for preparation of its federal, state and local income or franchise tax
or information returns, including each Member's pro rata share of Net Profits,
Net Losses and any other items of income, gain, loss and deduction for such
fiscal year.

                           6.7.4    (a) The Board of Managers shall ensure that
all records, documents and information in any form, including without limitation
written and electronic ("RECORDS") of the Company that may reasonably be
expected to relate to any regulatory process in the United States or elsewhere
that may be applicable to the Company from time to time, or that have been or
may reasonably be expected to be used to support any regulatory submission made
by the Company in the United States or otherwise, whether related to any Product
or otherwise, are maintained as statutorily required, and in any event for a
period of not less than 20 years following the completion of the applicable
regulatory process, unless the Members unanimously agree otherwise.

                                    (b)      Each Member shall ensure that all
         Records of such Member that may reasonably be expected to relate to any
         regulatory process in

                                       20

<PAGE>

         the United State or elsewhere that may be applicable to any Product
         from time to time, or that have been or may reasonably be expected to
         be used to support any regulatory submission made by the Company or
         such Member in the United States or elsewhere related to any Product,
         are maintained indefinitely, and in any event for a period of not less
         than 20 years following the completion of the applicable regulatory
         process, unless the Members unanimously agree otherwise.

                                    (c)      Each Member agrees to provide the
         Company with copies of such Records required to be maintained under
         Section 6.7.4(b) as the Company may reasonably request from time to
         time. All such copies shall be prepared at the Company's expense, and
         shall be delivered to the Company within twenty-one (21) days of
         receipt by the applicable Member of a request for copies.

                           6.7.5    The Members (personally or through an
authorized representative) may, for purposes reasonably related to their
Interests, examine and copy (at their own cost and expense) the books and
records of the Company during reasonable business hours.

                  6.8      MEETINGS OF MEMBERS. At any time, and from time to
time, the Board of Managers or any Member may call a meeting of the Members. No
meeting of Members is required to be called or held unless called by the Board
of Managers or a Member. Written notice of a meeting, stating the place, date
and hour of the meeting and the purpose(s) for which the meeting is called,
shall be given by the Board of Managers to each Member entitled to vote at such
meeting not less than three (3) nor more than thirty (30) days in advance. The
Members holding a Majority in Interest entitled to vote, present in person or
represented by proxy, shall constitute a quorum at all meetings of the Members.
No minutes of the meetings shall be required to be taken, but the Board of
Managers may cause minutes of one or more meetings to be taken by the Secretary
of the Company.

                  6.9      POWER TO BIND COMPANY. Except as expressly set forth
in this Agreement, no Member shall have the power or authority to bind the
Company.

                  6.10     STANDARDS OF CONDUCT.

                           6.10.1   To the extent that any Manager, any Member
or any Affiliate or subsidiary thereof, or any officer, director, employee or
agent of the Company or any of the foregoing (each, a "RESPONSIBLE PARTY") has,
at law or in equity, duties (including, without limitation, fiduciary duties) to
the Company, any Member or any other Person bound by the terms of this
Agreement, such Responsible Parties acting in accordance with this Agreement
shall not be liable to the Company, any Member or any such other Person for its
good faith reliance on the provisions of this Agreement. The provisions of this
Agreement, to the extent that they restrict the duties of a Responsible Party
otherwise existing at law or in equity, are agreed by all parties hereto to
replace such other duties to the greatest extent permitted under applicable law.

                           6.10.2   Whenever a Responsible Party is required or
permitted to make a decision, take or approve an action, or omit to do any of
the foregoing: (a) in its discretion, under a similar grant of authority or
latitude, or without an express standard of behavior

                                       21

<PAGE>

(including, without limitation, standards such as "reasonable" or "good faith"),
then such Responsible Party shall be entitled to consider only such interests
and factors, including its own, as it desires, and shall have no duty or
obligation to consider any other interests or factors whatsoever; or (b) with an
express standard of behavior (including, without limitation, standards such as
"reasonable" or "good faith"), then such Responsible Party shall comply with
such express standard but shall not be subject to any other, different or
additional standard imposed by this Agreement or otherwise under applicable law.

                           6.10.3   Notwithstanding anything in this Agreement
to the contrary, to the maximum extent permitted by Delaware law, the Members
absolutely and irrevocably waive any and all claims, actions, causes of action,
loss, cost, damage and expense, including, without limitation, any and all
attorneys' fees and other costs of enforcement arising out of or in connection
with any breach of any fiduciary duty by any Manager or any of their respective
Affiliates in the nature of actions taken or omitted by any such entity as a
Manager of this Company, which actions or omissions would otherwise constitute
the breach of any fiduciary duty owed to the Members (or any of them). It is the
express intent of the Members that the Managers and each and all of their
respective Affiliates shall be and hereby are relieved of any and all fiduciary
duties which might otherwise arise out of or in connection with this Agreement
to the Members (or any of them).

                  6.11     OUTSIDE ACTIVITIES OF MEMBERS. The Members and the
Managers may engage or invest in and devote their time to, any other business
venture or activity of any nature and description (independently or with
others), whether or not such other activity may be deemed or construed to be in
competition with the Company. Neither the Company nor any other Member shall
have any right by virtue of this Agreement or the relationship created hereby in
or to such other venture or activity of any Member (or to the income or proceeds
derived therefrom), and the pursuit thereof, even if competitive with the
business of the Company, shall not be deemed wrongful or improper.

                                   ARTICLE 7
                      INTERESTS AND TRANSFERS OF INTERESTS

                  7.1      TRANSFERS OF MEMBERSHIP INTERESTS.

                           7.1.1    Subject to the provisions of Section 7.6, a
Member may make or permit a Transfer, directly or indirectly, by operation of
law or otherwise, voluntarily or involuntarily, of all or any portion of its
Membership Interest, including all or any portion of its Economic Interest, only
to as follows:

                                    (a)      to an Affiliate of such Member; or

                                    (b)      to any Person other than an
         Affiliate of such Member, subject to the right of first refusal or the
         other Members as set forth in Section 7.2

                           7.1.2    Any other purported Transfer of a Membership
Interest or Economic Interest shall be null and void. A Substitute Member may
Transfer the transferred

                                       22

<PAGE>

Membership Interest or Economic Interest in the same manner as an original or
the transferring Member.

                           7.1.3    Notwithstanding the above or any contrary
provision in this Agreement, unless expressly waived by the Board of Managers in
writing, any otherwise permitted Transfer shall be null and void if:

                                    (a)      such Transfer would cause a
         termination of the Company for federal, state or local (if applicable)
         income tax purposes;

                                    (b)      such Transfer would, in the opinion
         of counsel to the Company, cause the Company to cease to be classified
         as a partnership for federal or state income tax purposes;

                                    (c)      such Transfer requires the
         registration of such transferred Interest pursuant to any applicable
         federal or state securities laws;

                                    (d)      such Transfer causes the Company to
         become a "Publicly Traded Partnership," as such term is defined in
         Section 7704 of the Code;

                                    (e)      such Transfer subjects the Company
         to regulation under the Investment Company Act of 1940, the Investment
         Advisers Act of 1940 or the Employee Retirement Income Security Act of
         1974, each as amended;

                                    (f)      such Transfer results in a
         violation of applicable laws;

                                    (g)      such Transfer is made to any Person
         who lacks the legal right, power or capacity to own such Interest; or

                                    (h)      the Company does not receive
         written instruments (including, without limitation, copies of any
         instruments of Transfer and such Assignee's consent to be bound by this
         Agreement as an Assignee) that are in a form satisfactory to the legal
         counsel of the Company.

                  7.2      SALE OR TRANSFER OF A MEMBER'S INTEREST. Except as
otherwise provided herein and in Section 7.1 hereof, no Member nor such Member's
heirs, personal representatives, successors or assigns (a "SELLING MEMBER")
shall have the right to Transfer all or any portion of his Membership Interest
or Economic Interest unless such Selling Member shall first deliver a notice in
writing to the Board of Managers, stating the price, terms and conditions of
such proposed Transfer and the identity of the proposed transferee. The Board of
Managers shall provide written notice to the other Members of the proposed
Transfer. For a period of thirty (30) days after issuance of such notice, the
other Members shall have the right to elect to purchase all of the Interest so
proposed to be transferred upon the same terms and conditions. If the other
Members or a portion of them collectively elect to purchase more than the entire
Interest proposed to be transferred, then each such Member shall be entitled to
purchase his Proportionate share of such Interest plus his Proportionate share
of the Interest which remains available for purchase pursuant to this Section
7.2. If the Members do not timely elect pursuant hereto to the purchase the
entire Interest proposed to be transferred by the Selling Member, the

                                       23

<PAGE>

Selling Member may within sixty (60) days thereafter complete the sale or
Transfer upon the terms originally proposed. In the event that the Selling
Member does not complete the sale or transfer of his Membership Interest or
Economic Interest within such sixty (60) day period, then the rights of the
Members under this Section 7.2 shall be reinstated and apply to any subsequent
sale or Transfer of such Interest proposed by the Selling Member.

                  7.3      RIGHTS OF ASSIGNEES. Until such time, if any, as a
transferee of any permitted Transfer pursuant to this Article 7 is admitted to
the Company as a Substitute Member pursuant to Section 7.6: (i) such transferee
shall be an Assignee only, and only shall receive, to the extent Transferred,
the distributions and allocations of income, gain, loss, deduction, credit or
any similar item to which the Member which Transferred its Interest would be
entitled; and (ii) such Assignee shall not be entitled or enabled to exercise
any other rights or powers of a Member, such other rights remaining with the
transferring Member. In such a case, the transferring Member shall remain a
Member even if he has transferred his entire Economic Interest in the Company to
one or more Assignees. In the event any Assignee desires to make a further
assignment of any Economic Interest in the Company, such Assignee shall be
subject to all of the provisions of this Agreement to the same extent and in the
same manner as any Member desiring to make such an assignment.

                  7.4      ADMISSIONS, WITHDRAWALS AND REMOVALS. No Person shall
be admitted to the Company as a Member except pursuant to Sections 3.1.2 or
3.2.1 (in the case of Persons obtaining an interest in the Company directly from
the Company) or Section 7.6 (in the case of transferees of a permitted Transfer
of an interest in the Company from another Person). Except as otherwise
specifically set forth in Section 7.7, no Member shall be entitled to retire or
withdraw from being a Member of the Company without the written consent of the
Board of Managers (which consent may be granted or withheld by the Board of
Managers). Without in any way affecting Section 6.2.3, no Member shall be
subject to removal. No admission or withdrawal of a Member shall cause the
dissolution of the Company. Any purported admission or withdrawal that is not in
accordance with this Agreement shall be null and void.

                  7.5      NO PAYMENT UPON WITHDRAWAL OF MEMBER. If any Member
withdraws from the Company with or without the consent of the Board of Managers
(other than pursuant to Section 7.7), then such Member shall not be entitled to
receive from the Company any payment whatsoever.

                  7.6      ADMISSION OF ASSIGNEES AS SUBSTITUTE MEMBERS.

                           7.6.1    An Assignee shall become a Substitute Member
only if and when each of the following conditions are satisfied:

                                    (a)      the assignor of the Interest
         transferred sends written notice to the Board of Managers requesting
         the admission of the Assignee as a Substitute Member and setting forth
         the name and address of the Assignee, the Percentage Interest
         transferred, and the effective date of the Transfer;

                                    (b)      the Board of Managers consents in
         writing to such admission, which consent may be granted or withheld by
         the Board of Managers; and

                                       24

<PAGE>

                                    (c)      the Board of Managers receives from
         the Assignee (i) such information concerning the Assignee's financial
         capacities and investment experience as may be requested by the Board
         of Managers and (ii) written instruments (including, without
         limitation, copies of any instruments of Transfer and such Assignee's
         consent to be bound by this Agreement as a Substitute Member) that are
         in a form satisfactory to the legal counsel of the Company.

                           7.6.2    Upon the admission of any Substitute Member,
Exhibit A shall be amended to reflect the name, address and Percentage Interest
of such Substitute Member and to eliminate or adjust, if necessary, the name,
address and Percentage Interest of the predecessor of such Substitute Member.

                           7.6.3    Notwithstanding anything to the contrary
contained in this Agreement, no Member may transfer more than such Member's
Economic Interest to any Person without the unanimous written consent of the
other Members. Any Member that transfers its Economic Interest shall remain
bound by this Agreement, provided that such Member shall not be entitled to
exercise any voting rights or rights to designate Managers under this Agreement.

                  7.7      WITHDRAWAL OF MEMBERS. If a Member has transferred
all of its Membership Interest to one or more Assignees, then such Member shall
withdraw from the Company if and when all such Assignees have been admitted as
Substitute Members in accordance with this Agreement.

                                   ARTICLE 8
                   LIABILITY, EXCULPATION, AND INDEMNIFICATION

                  8.1      LIABILITY. Except as otherwise provided by the
Delaware LLC Act, the debts, obligations and liabilities of the Company, whether
arising in contract, tort or otherwise, shall be solely the debts, obligations
and liabilities of the Company, and no Manager, Member or any proper delegate
shall be obligated personally for any such debt, obligation or liability of the
Company solely by reason of being a Manager, a Member or a delegate.

                  8.2      EXCULPATION.

                           8.2.1    No Covered Person shall be liable to the
Company or any other Covered Person for any loss, damage or claim incurred by
reason of any act or omission performed or omitted by such Covered Person in
good faith on behalf of the Company and in a manner reasonably believed to be
within the scope of authority conferred on such Covered Person by this
Agreement, except that a Covered Person shall be liable for any such loss,
damage or claim incurred by reason of such Covered Person's gross negligence or
willful misconduct.

                           8.2.2    A Covered Person shall be fully protected in
relying in good faith upon the records of the Company and upon such information,
opinions, reports or statements presented to the Company by any Person as to
matters the Covered Person reasonably believes are within such other Person's
professional or expert competence and who has been selected with reasonable care
by or on behalf of the Company, including information, opinions, reports or
statements as to the value and amount of the assets, liabilities, Net Profits,
Net Losses or net cash

                                       25

<PAGE>

flow or any other facts pertinent to the existence and amount of assets from
which distributions to Members might properly be paid.

                  8.3      INDEMNIFICATION OF COVERED PERSONS. To the fullest
extent permitted by applicable law, a Covered Person shall be entitled to
indemnification from the Company for any loss, damage or claim incurred by such
Covered Person by reason of any act or omission performed or omitted by such
Covered Person (including alleged breaches of fiduciary duty) in good faith on
behalf of the Company and in a manner reasonably believed to be within the scope
of authority conferred on such Covered Person by this Agreement, except that no
Covered Person shall be entitled to be indemnified in respect of any loss,
damage or claim incurred by such Covered Person by reason of gross negligence or
willful misconduct with respect to such acts or omissions; provided, however,
that any indemnity under this Section 8.3 shall be provided out of and to the
extent of Company Assets only, and no Manager or Member shall have any personal
liability with respect to such indemnity.

                  8.4      EXPENSES. To the fullest extent permitted by
applicable law, expenses (including legal fees) incurred by a Covered Person in
defending any claim, demand, action, suit or proceeding shall, from time to
time, be advanced by the Company prior to the final disposition of such claim,
demand, action, suit or proceeding upon receipt by the Company of an undertaking
by or on behalf of the Covered Person to repay such amount if it shall be
determined that the Covered Person is not entitled to be indemnified as
authorized in Section 8.3 hereof.

                  8.5      INSURANCE. The Company may purchase and maintain
insurance, to the extent and in such amounts as the Board of Managers shall deem
prudent, on behalf of Covered Persons and such other Persons as the Board of
Managers shall determine, against any liability that may be asserted against or
expenses that may be incurred by any such Person in connection with the
activities of the Company or such indemnities, regardless of whether the Company
would have the power to indemnify such Person against such liability under the
provisions of this Agreement. The Company may enter into indemnity contracts
with Covered Persons and such other Persons as the Board of Managers shall
determine and adopt written procedures pursuant to which arrangements are made
for the advancement of expenses and the funding of obligations under Section 8.4
hereof and containing such other procedures regarding indemnification as the
Board of Managers considers appropriate.

                                   ARTICLE 9
            DISSOLUTION, LIQUIDATION, AND TERMINATION OF THE COMPANY

                  9.1      LIMITATIONS. The Company may be dissolved, liquidated
and terminated only pursuant to the provisions of this Article 9, and the
parties hereto do hereby irrevocably waive any and all other rights they may
have to cause a dissolution of the Company or a sale or partition of any or all
of the Company Assets.

                  9.2      EXCLUSIVE CAUSES. Notwithstanding the Delaware LLC
Act, the following and only the following events shall cause the Company to be
dissolved, liquidated and terminated:

                                       26

<PAGE>

                           9.2.1    The election of NeoTherapeutics or JBPCL at
any time after six (6) months after the Effective Date if there is no Supply
Agreement between the Company and JBCPL at the time of such election;

                           9.2.2    The election of NeoTherapeutics at any time
after a violation by JBCPL and/or JBSOL of Section 6.11;

                           9.2.3    The election of NeoTherapeutics at any time
when the Managers designated by NeoTherapeutics represent less than a majority
of the Board of Managers;

                           9.2.4    The occurrence of a Terminating Capital
Transaction;

                           9.2.5    The unanimous agreement of the Members; or

                           9.2.6    The entry of a decree of judicial
dissolution under Section 18-802 of the Delaware LLC Act.

                           Any dissolution of the Company other than as provided
in this Section 9.2 shall be a dissolution in contravention of this Agreement.

                  9.3      EFFECT OF DISSOLUTION. The dissolution of the Company
shall be effective on the day on which the event occurs giving rise to the
dissolution, but the Company shall not terminate until it has been wound up and
its assets have been distributed as provided in Section 9.5 of this Agreement.
Notwithstanding the dissolution of the Company, prior to the termination of the
Company, the business of the Company and the affairs of the Members, as such,
shall continue to be governed by this Agreement.

                  9.4      NO CAPITAL CONTRIBUTION UPON DISSOLUTION. Each Member
shall look solely to the assets of the Company for all distributions with
respect to the Company, its Capital Contribution(s) thereto, its Capital Account
and its share of Net Profits or Net Losses, and shall have no recourse therefor
(upon dissolution or otherwise) against any other Member. Accordingly, if any
Member has a deficit balance in its Capital Account (after giving effect to all
contributions, distributions and allocations for all taxable years, including
the year during which the liquidation occurs), then such Member shall have no
obligation to make any Capital Contribution with respect to such deficit, and
such deficit shall not be considered a debt owed to the Company or to any other
Person for any purpose whatsoever.

                  9.5      LIQUIDATION.

                           9.5.1    Upon dissolution of the Company, one of the
Managers (such person to be designated by the Board of Managers) shall act as
the "LIQUIDATOR" of the Company. The Liquidator shall liquidate the assets of
the Company, and after allocating (pursuant to Article 5 of this Agreement) all
income, gain, loss and deductions resulting therefrom, shall apply and
distribute the proceeds thereof as follows:

                                       27

<PAGE>

                                    (a)      first, to the payment of the
         obligations of the Company (including any voluntary Member loans under
         Section 3.2(b)), to the expenses of liquidation and to the setting up
         of Reserves; and

                                    (b)      thereafter, to the Members pursuant
         to Section 4.2.

                           9.5.2    Notwithstanding Section 9.5.1 of this
         Agreement, in the event that the Liquidator reasonably determines that
         an immediate sale of all or any portion of the Company Assets would
         cause undue loss to the Members, the Liquidator, in order to avoid such
         loss to the extent not then prohibited by the Delaware LLC Act, may
         either defer liquidation of and withhold from distribution for a
         reasonable time any Company Assets except those necessary to satisfy
         the Company's debts and obligations, or distribute the Company Assets
         to the Members in kind.

                                   ARTICLE 10
                                  MISCELLANEOUS

                  10.1     AMENDMENTS.

                           10.1.1   Each Additional Member and Substitute Member
shall become a signatory hereto by signing such number of counterpart signature
pages to this Agreement and such other instruments, in such manner, as the Board
of Managers shall determine. By so signing, each Additional Member and
Substitute Member, as the case may be, shall be deemed to have adopted and to
have agreed to be bound by all of the provisions of this Agreement.

                           10.1.2   Subject to Sections 6.4 hereof, this
Agreement may be amended at any time and from time to time by execution of a
written agreement executed by each member of the Board of Managers and at least
a Majority in Interest of the Members.

                           10.1.3   In making any amendments, the Board of
Managers shall prepare and file such documents and certificates as may be
required under the Delaware LLC Act and under the laws of any other jurisdiction
applicable to the Company.

                  10.2     ACCOUNTING AND FISCAL YEAR. Subject to Section 448 of
the Code, the books of the Company shall be kept on such method of accounting
for tax and financial reporting purposes as may be determined by the Board of
Managers. The fiscal year of the Company shall end on December 31 of each year,
or on such other date required or permitted under the Code as the Board of
Managers shall determine.

                  10.3     ENTIRE AGREEMENT. This Agreement constitutes the
entire agreement between the parties hereto pertaining to the subject matter
hereof and fully supersedes any and all prior or contemporaneous agreements or
understandings between the parties hereto pertaining to the subject matter
hereof.

                  10.4     FURTHER ASSURANCES. Each of the parties hereto does
hereby covenant and agree on behalf of itself, its successors and its assigns,
without further consideration, to prepare, execute, acknowledge, file, record,
publish and deliver such other instruments,

                                       28

<PAGE>

documents and statements, and to take such other action, as may be required by
law or reasonably necessary to effectively carry out the purposes of this
Agreement.

                  10.5     NOTICES. Any notice, consent, payment, demand or
communication required or permitted to be given by any provision of this
Agreement shall be in writing and shall be (a) delivered personally to the
Person or to an officer of the Person to whom the same is directed or (b) sent
by registered or certified mail, return receipt requested, postage prepaid,
addressed as follows: if to the Company, to the Company at the address set forth
in Section 1.3 hereof, or to such other address as the Company may from time to
time specify by notice to the Members; if to a Member, to such Member at the
address set forth in Exhibit A, or to such other address as such Member may from
time to time specify by notice to the Company. Any such notice shall be deemed
to be delivered, given and received for all purposes as of: (i) the date so
delivered, if delivered personally; or (ii) on the date of receipt or refusal
indicated on the return receipt, if sent by registered or certified mail, return
receipt requested, postage and charges prepaid and properly addressed.

                  10.6     TAX MATTERS.

                           10.6.1   Samuel Gulko shall be designated and shall
operate as "TAX MATTERS PARTNER" (as defined in Section 6231 of the Code), to
oversee or handle matters relating to the taxation of the Company.

                           10.6.2   The Tax Matters Partner may make all
elections for federal income and all other tax purposes (including, without
limitation, pursuant to Section 754 of the Code).

                           10.6.3   Income tax returns of the Company shall be
prepared by such certified public accountant(s) as the Board of Managers shall
retain at the expense of the Company.

                  10.7     GOVERNING LAW; CERTAIN WAIVERS. This Agreement,
including its existence, validity, construction and operating effect, and the
rights of each of the parties hereto, shall be governed by and construed in
accordance with the laws of the State of Delaware without regard to otherwise
governing principles of conflicts of law. The Members waive any and all rights
they may have to a jury trial, and any and all rights they may have to punitive,
special, exemplary or consequential damages, in respect of any dispute based on
this Agreement.

                  10.8     CAPTIONS - PRONOUNS. Any titles or captions contained
in this Agreement are for convenience only and shall not be deemed part of the
text of this Agreement. All pronouns and any variations thereof shall be deemed
to refer to the masculine, feminine, neuter, singular or plural as appropriate.

                  10.9     BINDING EFFECT. Except as otherwise expressly
provided herein, this Agreement shall be binding on and inure to the benefit of
the Members, their heirs, executors, administrators, successors and all other
Persons hereafter holding, having or receiving an interest in the Company,
whether as Assignees, Substitute Members or otherwise.

                                       29

<PAGE>

                  10.10    CONFIDENTIALITY. Each party hereto agrees that the
provisions of this Agreement, all understandings, agreements and other
arrangements between and among the parties, and all other non-public information
received from or otherwise relating to, the Company shall be confidential, and,
except as otherwise required by law, shall not be disclosed or otherwise
released to any other Person (other than to such party's legal counsel or
another party hereto), without the written consent of the Board of Managers
(which shall not be unreasonably withheld or delayed). The obligations of the
parties hereunder shall not apply to the extent that the disclosure of
information otherwise determined to be confidential is required by applicable
law, provided that, prior to disclosing such confidential information, a party
shall notify the Company thereof, which notice shall include the basis upon
which such party believes the information is required to be disclosed.

                  10.11    MEMBER REPRESENTATIONS. Each Member acknowledges,
agrees and represents to the Company and each other Member that (a) he or she is
an "accredited investor," as that term is defined in Regulation D promulgated
under the Securities Act, (b) he or she either (i) has a preexisting personal or
business relationship with the Company or any of its members, officers, Managers
or controlling Persons or (ii) by reason of his or her business or financial
experience or the business or financial experience of his or her professional
advisors who are unaffiliated with and who are not compensated by the Company or
any affiliate or selling agent of the Company, directly or indirectly, has the
capacity to protect his or her own interests in connection with an investment in
the Company, (c) he or she has been furnished with all documents and additional
information requested by him or her for the purpose of evaluating whether an
investment in the Company is suitable for the Member, (d) in evaluating an
investment in the Company, the Member has consulted with his or her own
investment, legal and tax advisors and has independently concluded that an
investment by the Member in the Company is appropriate in light of his or her
overall investment objectives and financial situation, (e) the Member has
adequate means of providing for current needs and contingencies, has no need for
liquidity with respect to his or her investment in the Company and is able to
bear the economic risk of a loss of the Member's entire investment in the
Company, (f) the Member is purchasing his or her interest for the Member's own
account for investment and not with a view to, or for resale in connection with,
any distribution of such security, and (g) the Member understands there are no
guarantees or assurances of any economic or other benefits that may accrue by
virtue of holding an interest in the Company. Each Member further acknowledges,
agrees and represents that he or she is not relying on legal counsel of any
other Member in reviewing this Agreement and in deciding whether to invest as a
Member. In this connection, each Member acknowledges and agrees that Latham &
Watkins has represented solely NeoTherapeutics and certain of its Affiliates in
putting together this Agreement and that, although Latham & Watkins may continue
to represent NeoTherapeutics and certain of its Affiliates on various matters
from time to time, all Members consent to the representation by Latham & Watkins
of the Company from time to time upon its request.

                  10.12    COUNTERPARTS. This Agreement may be executed in any
number of multiple counterparts, each of which shall be deemed to be an original
copy and all of which shall constitute one agreement, binding on all parties
hereto.

                  10.13    ATTORNEY FEES. In case any proceeding, whether at
law, in equity or in arbitration, shall be brought by any Member or by or on
behalf of the Company to enforce the

                                       30

<PAGE>

terms of this Agreement or with respect to any breach hereof, the prevailing
party in each such proceeding, as determined by the court or arbitrator, shall
be entitled to the payment of reasonable attorneys' fees and costs from the
non-prevailing party or parties (as determined by the court or arbitrator).

                  10.14    TITLES. Article and Section titles are for
descriptive purposes only and shall not control or alter the meaning of this
Agreement as set forth in the text.

                  10.15    SUCCESSORS. This Agreement shall bind and inure to
the benefit of the Members' respective successors and assigns.

                  10.16    COMPUTATION OF TIME PERIODS. All periods of time
referred to in this Agreement shall include Saturdays, Sundays and state or
national holidays, provided that if the date or last date to perform any act or
give any notice or approval shall fall on a Saturday, Sunday or state or
national holiday, such act or notice may be timely performed or given on the
next succeeding day which is not a Saturday, Sunday or state or national
holiday.

                  10.17    SEVERABILITY. Should any one or more of the
provisions of this Agreement or of any agreement entered into pursuant to this
Agreement be determined to be illegal or unenforceable, then such illegal or
unenforceable provision shall be modified by the proper court or arbitrator to
the minimum extent necessary and possible to make such provision enforceable,
and such modified provision and all other provisions of this Agreement and of
each other agreement entered into pursuant to this Agreement shall be given
effect separately from the provision or portion thereof determined to be illegal
or unenforceable and shall not be affected thereby.

                  10.18    SIGNATORY AUTHORITY. By signing this Agreement, the
individual or individuals signing this Agreement on behalf of each Member
represents to the other Members that he or she has full authority to do so, has
received all required consents, and that his or her signature (together with the
signature or signatures of any other individual signing below on behalf of such
Member) is (are) the only signatures required to bind the Member on whose behalf
he or she is signing this Agreement.

                  10.19    ARBITRATION. Any disputes which arise involving all
or any of the Members under this Agreement, shall be subject to final, binding
arbitration upon written request by any Member involved in the dispute in
accordance with this Section 10.20. The dispute shall be submitted before
JAMS/Endispute ("JAMS") within thirty (30) days after the requesting notice in
accordance with the then existing JAMS Arbitration Rules as modified by this
Section 10.20; a decision shall be issued within thirty (30) days after the
close of the record; and judgment upon the award may be entered in any court
having jurisdiction over the judgment. Within thirty (30) days after selection
of the arbitrator as provided herein, each party to the dispute shall submit to
each other and the arbitrator their respective proposals for resolution of the
dispute, and the arbitration shall be limited to the sole question of
determining which written proposal is to be accepted. The arbitrator shall have
no authority to compromise between the proposals. If a party to a dispute fails
to appear at any properly noticed arbitration proceeding, an award may be
entered against such party notwithstanding such failure to appear. If the
parties disagree on the arbitrator, the parties shall jointly request JAMS to
furnish a list of five (5)

                                       31

<PAGE>

available arbitrators. After receipt of such list and an opportunity to consider
the names, each party may designate in writing to JAMS not more than two (2)
names to be eliminated from the selection process. If more than one (1) name
remains after such eliminations are made, the selection of the arbitrator shall
be made by lot from the remaining names. If either party makes demand upon the
other for arbitration, the arbitration shall be conducted in Orange County,
California at the location designated by the arbitrator. The parties may
mutually agree to another location. Subject to Section 10.14, the expenses,
wages and other compensation of any witnesses called before the arbitrator shall
be borne by the party calling the witnesses. Subject to Section 10.14, other
expenses incurred, including wages of participants and experts shall be borne
separately by the respective parties. Subject to Section 10.14, the fee for the
arbitration, the arbitrator's fees and expenses, the cost of any hearing room,
and the cost of a shorthand or similar reporter and the original transcript
shall all be borne by the Company.

                  10.20    LOCKUP IN EVENT OF INITIAL PUBLIC OFFERING. Each
Member acknowledges that the Company may at some time reorganize, change or
convert its form of entity into a corporation in contemplation of an initial
public offering. Each Member agrees (a) that, during a period of 180 days from
the date of such initial public offering, whether or not such reorganization,
change or conversion has occurred, such Member will not, without the prior
written consent of the underwriter(s) of the initial public offering, directly
or indirectly, sell, offer to sell, grant any option or right for the sale of,
or otherwise dispose of or transfer, any Membership Interests (or shares of
common stock or other securities of a successor corporation or entity of the
Company into which the Company may reorganize in contemplation of an initial
public offering) and (b) to execute an agreement reflecting the obligations
described in clause (a) above as may be requested by the underwriter(s) at the
time of the initial public offering of the Company (or any successor corporation
or entity of the Company into which the Company may reorganize in contemplation
of an initial public offering).

                  10.21    INTERPRETATIONS. Neither this Agreement nor any
uncertainty or ambiguity herein shall be construed or resolved against any party
hereto, whether under any rule of construction or otherwise. No party to this
Agreement shall be considered the draftsman. On the contrary, this Agreement has
been reviewed, negotiated and accepted by all parties and their attorneys and
shall be construed and interpreted according to the ordinary meaning of the
words used so as fairly to accomplish the purposes and intentions of all parties
hereof.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                       32

<PAGE>

                  IN WITNESS WHEREOF, the parties hereto have duly executed this
Agreement as of the Effective Date.

                                             BOARD OF MANAGERS:

                                             /s/ Alvin J. Glasky
                                             -----------------------------------
                                             [Alvin J. Glasky, Ph.D.]

                                             /s/ Rajesh C. Shrotriya
                                             -----------------------------------
                                             [Rajesh C. Shrotriya, M.D.]

                                             /s/ Satya Agarwala
                                             -----------------------------------
                                             [Satya Agarwala, M.D.]

                                             /s/ Samuel Gulko
                                             -----------------------------------
                                             [Samuel Gulko]

                                             /s/ Ashok Gore
                                             -----------------------------------
                                             [Ashok Gore, Ph.D.]

<PAGE>

                       LIMITED LIABILITY COMPANY AGREEMENT

                                       OF

                                    NEOJB LLC

                        COUNTERPART MEMBER SIGNATURE PAGE

THE MEMBER INTERESTS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE OFFERED FOR
SALE, SOLD OR OTHERWISE TRANSFERRED UNLESS (A) COVERED BY AN EFFECTIVE
REGISTRATION STATEMENT UNDER SUCH ACT AND QUALIFICATION ORDERS UNDER SUCH LAWS
OR (B) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND
QUALIFICATION ORDERS UNDER SUCH LAWS, THE AVAILABILITY OF WHICH IS ESTABLISHED
TO THE SATISFACTION OF THE BOARD OF MANAGERS.

                  By execution of this counterpart member signature page, the
undersigned does hereby become a party to the Limited Liability Company
Agreement of NeoJB LLC, effective as of April 16, 2002 (the "Agreement"). The
undersigned hereby agrees to be bound by all of the terms and conditions of the
Agreement and authorizes the Board of Managers to attach this counterpart
signature page to the Agreement and, when so attached with the signature pages
of all of the Members, such Agreement will constitute one and the same document
as if all signatories had originally signed thereon.

ADDRESS:                                     MEMBER:

"Neelam Centre"                              J. B. Life Science Overseas Limited
'B' Wing, 4th Floor
Hind Cycle Road                              By:    /s/ J. B. Mody
Worli, Mumbai 400025                                ----------------------------
India                                        Name:  J. B. Mody
                                             Title: Director

ADDRESS:                                     MEMBER:

157 Technology Drive                         NeoTherapeutics, Inc.
Irvine, CA 92618
U.S.A.                                       By:    /s/ Alvin J. Glasky
                                                    ----------------------------
                                             Name:  Alvin J. Glasky, Ph.D.
                                             Title: Chairman & Chief Executive
                                             Officer

<PAGE>

                                    EXHIBIT A

                         MEMBERS, CAPITAL CONTRIBUTIONS
                            AND PERCENTAGE INTERESTS

1.       Class A Members:

<TABLE>
<CAPTION>
       CLASS A MEMBER                 CAPITAL CONTRIBUTION    PERCENTAGE INTEREST
<S>                                   <C>                     <C>
NeoTherapeutics, Inc.                      $80,000.00                 80%
157 Technology Drive
Irvine, California 92618

J.B. Life Science Overseas Limited         $20,000.00                 20%
</TABLE>

                                      A-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}]]